<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2-6072-25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LEPONEX 100MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CLOZAPINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        145.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Madaus GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Madaus GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 5165]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Viatris Arabia Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Viatris Pharma GmbH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AH02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Leponex tablets contain an active substance called clozapine. This medicine</p><p>belongs to a group of medicines called antipsychotics.</p><p><strong>&nbsp;</strong></p><p><strong>What Leponex is used for?</strong></p><p>Leponex is used to treat people suffering from schizophrenia who have</p><p>either tried other antipsychotic medications and did not benefit sufficiently</p><p>or who are unable to tolerate other antipsychotic medications because of</p><p>side effects.</p><p>Leponex is also used to treat people suffering from schizophrenia or</p><p>schizoaffective disorder (schizophrenia with mood disorders) who might</p><p>otherwise attempt to commit suicide. Schizophrenia is a mental illness</p><p>involving disturbances in thinking, emotional reactions and behaviour.</p><p>In addition, Leponex is used to treat thought, emotional and behavioural</p><p>disturbances in patients with Parkinson&rsquo;s disease, when standard treatment</p><p>has failed. Parkinson&rsquo;s disease is a chronic (persistent) disorder of the brain.</p><p>It mainly affects the way the brain co-ordinates the movements of the</p><p>muscles in various parts of the body.</p><p><strong>&nbsp;</strong></p><p><strong>How Leponex works</strong></p><p>Leponex predominantly works by binding to and blocking the D4 receptor</p><p>(or dopamine receptor) in the brain. Leponex also has weak binding and</p><p>blocking activity on the D1, D2, D3 and D5 receptors in the brain as well as</p><p>other receptors that potentially have some contribution to its effectiveness.</p><p><strong>Monitoring during your treatment with Leponex</strong></p><p>You will have regular blood tests for as long as you continue to take Leponex</p><p>and for four weeks after stopping the treatment. Your doctor will tell you</p><p>when to have the tests. <strong>It is important that you attend for all blood tests</strong></p><p><strong>recommended by your doctor. </strong>If you suffer from high level of sugar in the</p><p>blood (diabetes) your doctor may regularly check your level of sugar in the</p><p>blood. Leponex may cause alteration in blood lipids. Leponex may cause</p><p>weight gain. Your doctor may monitor your weight and blood lipid levels. If</p><p>you have any questions about how Leponex works or why this medicine has</p><p>been prescribed for you, ask your doctor.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Leponex may only be taken if prescribed by a doctor.</p><p>Follow all doctors&rsquo; instructions carefully, even if they differ from the general</p><p>information contained in this leaflet.</p><p>Before starting Leponex, you will have a blood test to make sure that you</p><p>can take this medicine.</p><p><strong>Do not take Leponex</strong></p><p><strong>&bull; If you are allergic </strong>to clozapine or any of the ingredients of Leponex</p><p>listed at the end of this leaflet.</p><p><strong>&bull; If you are </strong>unable to undergo regular blood tests.</p><p><strong>&bull; If you have </strong>ever been diagnosed with low white blood cells except if it</p><p>was following a treatment for cancer.</p><p><strong>&bull; If you suffer or have ever suffered from </strong>bone marrow disease.</p><p><strong>&bull; If you have liver, </strong>kidney or heart problems.</p><p><strong>&bull; If you suffer from </strong>uncontrolled seizures.</p><p><strong>&bull; If you have </strong>problems with alcohol or drug abuse.</p><p><strong>&bull; If you suffer or have ever suffered from </strong>severe constipation, obstruction of</p><p>the bowel or any other condition which has affected your large bowel.</p><p>If any of the above applies to you, <strong>tell your doctor without taking Leponex.</strong></p><p>If you think you are allergic to Leponex (clozapine), ask your doctor for</p><p>advice before taking Leponex.</p><p><strong>&nbsp;</strong></p><p><strong>Take special care with Leponex</strong></p><p><strong>&bull; If you have </strong>had a stroke, heart disease or family history of abnormal</p><p>conduction in the heart called &ldquo;prolongation of the QT interval&rdquo;</p><p><strong>&bull; If you suffer from </strong>enlargement of the prostate, convulsions, glaucoma</p><p>(a condition in which the pressure of fluid in the eye is generally too high),</p><p>diabetes or any other serious medical condition.</p><p>If any of these apply to you, <strong>tell your doctor before you take Leponex.</strong></p><p><strong>&bull; Consult your doctor immediately </strong>at the first sign of a cold, influenza,</p><p>fever, sore throat, or any other infection. Leponex can reduce the</p><p>number of white cells in your blood, and lead to a higher sensitivity to</p><p>infection. Your doctor may check your blood cell count and take further</p><p>measures if necessary.</p><p><strong>&bull; Consult your doctor immediately if you experience </strong>fast and irregular</p><p>heart beat that persists when you are at rest, possibly accompanied by</p><p>shortness of breath and swelling of the feet or legs. These effects may</p><p>especially occur at the beginning of the treatment and your</p><p>doctor may need to take further measures.</p><p>During treatment with Leponex you may experience</p><p>&bull; Light-headedness or fainting, especially at the start of treatment. This is</p><p>due to a lowering of your blood pressure.</p><p>&bull; Seizures, drowsiness, fainting, muscle weakness, which may lead to falls</p><p>&bull; Chest pain which may be a symptom of heart attack which may lead to</p><p>death.</p><p>&bull; Chest pain which may be due to inflammation of the heart muscle</p><p>which may lead to death.</p><p>&bull; Abdominal pain and constipation which may be a sign of abnormal</p><p>dilatation of the large intestines which may lead to death</p><p>&bull; Abdominal pain which could be a sign of breakdown of part of the intestine</p><p>due to its compromised blood supply which may lead to death</p><p>&bull; Sleepiness and remaining in bed for prolonged duration in combination</p><p>with weight gain which may lead to blood clots in some patients.</p><p>If you get any of these symptoms, <strong>tell your doctor straight away.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Taking other medicines</strong></p><p>Tell your doctor or pharmacist if you are taking or have recently taken any</p><p>other medicines. Remember those not prescribed by a doctor. This includes</p><p>sleeping pills, tranquilizers, antiallergy medicines, antibiotics, medicines</p><p>used to treat depression, convulsions or ulcers of the stomach, and</p><p>medicines effective against fungal or viral infections, other medicines used</p><p>to treat mental illness, birth-control tablets. These medicines can interfere</p><p>with your treatment.</p><p><strong>&nbsp;</strong></p><p><strong>Taking Leponex with food and drink</strong></p><p>&bull; Interaction with alcohol: Leponex may enhance the effects of alcohol.</p><p>You should not drink alcohol while taking Leponex.</p><p>&bull; Levels of Leponex in the blood can be affected by stopping smoking or</p><p>changing in the number of caffeine-containing drinks you have in a day.</p><p><strong>Inform your doctor </strong>of any such changes in your habits.</p><p><strong>&nbsp;</strong></p><p><strong>Older people (age 60 years and over)</strong></p><p>Your doctor might need to adjust your treatment if you are 60 or older.</p><p>Tell your doctor or pharmacist if you suffer from a condition called</p><p>dementia.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p>The use of Leponex in children and adolescents is not recommended.</p><p><strong>Pregnancy and breast-feeding</strong></p><p><strong>Tell your doctor or pharmacist </strong>before using Leponex if you are pregnant or</p><p>you think that you may be pregnant. Your doctor will discuss with you the</p><p>benefits and potential risks of using this medicine during pregnancy.</p><p><strong>Tell your doctor immediately </strong>if you become pregnant during Leponex</p><p>treatment. New-born babies of mothers taking antipsychotic drugs during</p><p>the third trimester of pregnancy may have increased risk of developing stiff</p><p>limbs, trembling, agitation, muscle stiffness, muscle flaccidity, drowsiness,</p><p>short and shallow breathing, and feeding disorders following delivery. In</p><p>some cases these symptoms may be self-limiting, in other cases, babies</p><p>may require intensive care unit support or hospitalization.</p><p><strong>Tell your doctor or pharmacist </strong>if you are <em>breast-feeding. </em>Clozapine, the</p><p>active ingredient of Leponex/Clozaril, may pass into your milk and affect</p><p>your baby. You should not breast-feed during Leponex treatment.</p><p><strong>Women of child-bearing potential and contraception</strong></p><p>Some women taking some antipsychotic medications have irregular or no</p><p>periods. If you are female and you have been affected in this way, your periods</p><p>may return when your medication is changed to Leponex. In these</p><p>circumstances, you should make sure that you use a reliable method of</p><p>contraception.</p><p><strong>&nbsp;</strong></p><p><strong>Fertility:</strong></p><p>Limited data available on the effects of clozapine on human fertility are</p><p>inconclusive</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>Leponex may cause drowsiness, especially at the start of treatment. Therefore</p><p>you should avoid driving or using machines until you have got used to the</p><p>medication and drowsiness has disappeared.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow your doctor&rsquo;s instructions carefully. Do not exceed the</p><p>recommended dosage.</p><p><strong>&nbsp;</strong></p><p><strong>How much Leponex to take</strong></p><p>Your doctor will tell you exactly how many tablets of Leponex to take and how</p><p>often you should take them.</p><p><strong>&bull; Treatment of schizophrenia or schizoaffective disorders in people who</strong></p><p><strong>might otherwise attempt to commit suicide</strong></p><p>Treatment is usually started with one half of a 25 mg tablet (12.5 mg)</p><p>once or twice on the first day. Your doctor will then gradually increase</p><p>your dose, until the ideal dose for you is established.</p><p>Your treatment will continue with a daily dose of Leponex between 300</p><p>and 450 mg. The daily dose is usually taken in divided portions, some</p><p>being taken in the morning and some at bedtime. Some people may</p><p>require doses of up to a maximum of 900 mg per day.</p><p><strong>&bull; Treatment of thought, emotional and behavioural disturbances in</strong></p><p><strong>patients with Parkinson&rsquo;s disease</strong></p><p>Treatment is usually started with one half of a 25 mg tablet (12.5 mg) in</p><p>the evening, and then the dose will be gradually increased until the ideal</p><p>dose for you is established. Your treatment will continue with a daily dose</p><p>of Leponex between 25 mg and 37.5 mg, and will usually be given as a</p><p>single dose each evening.</p><p>Some people may require doses of up to 50 mg per day. In exceptional</p><p>cases, your doctor may prescribe a higher dose but the dose must never</p><p>exceed 100 mg per day. Your blood pressure will be measured during the</p><p>first weeks of treatment.</p><p><strong>&nbsp;</strong></p><p><strong>When to take Leponex</strong></p><p>Taking Leponex at the same time each day will help you remember when to</p><p>take your medicine.</p><p><strong>&nbsp;</strong></p><p><strong>How to take Leponex</strong></p><p>Take Leponex tablets by mouth. The scored tablets can be divided into equal</p><p>halves (the formulation may differ in some countries).</p><p><strong>&nbsp;</strong></p><p><strong>How long to take Leponex</strong></p><p>Continue taking Leponex as your doctor tells you.</p><p>If you have questions about how long to take Leponex, talk to your doctor or</p><p>your pharmacist.</p><p><strong>&nbsp;</strong></p><p><strong>If you take more Leponex than you should (an overdose)</strong></p><p>If you have accidentally taken too many tablets, <strong>talk to your doctor or</strong></p><p><strong>pharmacist straight away. </strong>You may require medical attention.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take Leponex</strong></p><p>If you forget to take a dose, take another as soon as your remember. However,</p><p>if it is time to take your next dose, or less than 4 hours before your next dose,</p><p>leave out your forgotten tablets and take your next dose at the right time.</p><p><strong>Do not </strong>take a double dose of Leponex to make up for the one that you missed.</p><p>If you have not taken Leponex for more than two days, do not re-start taking</p><p>the medicine and contact your doctor as soon as possible.</p><p><strong>&nbsp;</strong></p><p><strong>If you stop taking Leponex</strong></p><p><strong>Risk for withdrawal effects</strong></p><p><strong>Do not suddenly stop using Leponex.</strong></p><p>If this medicine must be stopped for any reason, your doctor will reduce the</p><p>dose gradually over a 1- to 2-week period to avoid side effects. Suddenly</p><p>stopping Leponex or rapidly reducing the dose can cause side effects. For this</p><p>reason, it is very important that you, and those caring for you, are able to</p><p>recognise signs of Leponex withdrawal.</p><p>If sudden discontinuation of Leponex is necessary, the patient may have</p><p>psychotic symptoms and withdrawal symptoms such as profuse sweating,</p><p>headache, nausea, vomiting, bronchial constriction and diarrhoea.</p><p><strong>If you have any of the above signs, tell your doctor straight away. These signs</strong></p><p><strong>may be followed by more serious side effects unless you are treated</strong></p><p><strong>immediately.</strong></p><p><strong>&nbsp;</strong></p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tell your doctor or pharmacist as soon as possible if you get any unexpected</p><p>symptoms while you are using Leponex, even if you do not think that they are</p><p>connected with the medicine.</p><p><strong>&nbsp;</strong></p><p><strong>Some side effects could be serious and need medical attention</strong></p><p><em>Very common: these side effects may affect more than 10 in every 100 patients</em></p><p>&bull; Fast heartbeat</p><p><em>Common: these side effects may affect between 1 and 10 in every 100 patients</em></p><p><strong>&bull; signs of infection </strong>such as fever, severe chills, sore</p><p>throat or mouth ulcers. Leponex can reduce the number of white cells in</p><p>your blood, and lead to a higher sensitivity to infection.</p><p>&bull; Seizures.</p><p>&bull; High level of a specific type of white blood cells, increased white blood cell</p><p>count.</p><p>&bull; Loss of consciousness, fainting.</p><p><em>Uncommon: these side effects may affect between 1 and 10 in every 1,000</em></p><p><em>patients</em></p><p>&bull; Fever, muscle cramps, fluctuation in blood pressure, disorientation,</p><p>confusion.</p><p><em>Rare: these side effects may affect between 1 and 10 in every 10,000 patients</em></p><p>&bull; Significant drop in blood pressure.</p><p>&bull; Chest pain due to inflammation of the heart muscle.</p><p>&bull; Chest pain due to inflammation of the outer lining</p><p>of the heart.</p><p>&bull; Blood clot.</p><p>&bull; Low level of red blood cells.</p><p>&bull; Food getting into the lung.</p><p>&bull; <strong>signs of respiratory tract infection or pneumonia </strong>such as fever, coughing,</p><p>difficulty breathing, wheezing.</p><p>&bull; Abdominal pain due to inflammation of the pancreas.</p><p>&bull; Yellow skin and eyes, nausea, and/or loss of appetite, dark urine sign of</p><p>liver disorder, hepatitis.</p><p><em>Very rare: these side effects may affect less than 1 in every 10,000 patients</em></p><p>&bull; Spontaneous bleeding or bruising possible signs of low level of blood</p><p>platelets (thrombocytopenia).</p><p>&bull; High platelet levels in the blood.</p><p>&bull; Impaired orientation/confusion, nausea/ vomiting, excessive urination,</p><p>abdominal pain with high blood sugar.</p><p>&bull; Chest pain, irregular heartbeat and heart failure.</p><p>&bull; Short and shallow breathing.</p><p>&bull; Feeling sick, vomiting with severe/prolonged constipation.</p><p>&bull; Yellow skin due to severe hepatitis, abdominal pain.</p><p>&bull; Inflammation of the kidney.</p><p>&bull; Prolonged erection.</p><p>&bull; Sudden unexplained death.</p><p>&bull; Kidney function problems.</p><p><em>Frequency not known: These side effects may also occur, but the frequency is not</em></p><p><em>known</em></p><p>&bull; Profuse sweating, headache, nausea, vomiting and diarrhea (symptoms of</p><p>cholinergic syndrome).</p><p>&bull; Falls due to Leponex -induced seizures, drowsiness, fainting, muscle</p><p>weakness.</p><p>&bull; Chest pain which may be a symptom of heart attack which may lead to</p><p>death.</p><p>&bull; Chest pain which may be a sign of inflammation of the heart muscle which</p><p>may lead to death</p><p>&bull; Crushing chest pain (signs of insufficient blood flow and oxygen to the</p><p>heart muscle).</p><p>&bull; Chest pain, cough, hiccups, rapid breathing (signs of fluid collection</p><p>between the layers of tissue that line the lungs and chest cavity)</p><p>&bull; Intermittent &ldquo;thumping,&rdquo; &ldquo;pounding,&rdquo; or &ldquo;fluttering&rdquo; sensation in the chest</p><p>(palpitations).</p><p>&bull; Rapid and irregular heartbeats (atrial fibrillation).</p><p>There may be occasional heart palpitations,fainting, shortness of breath,</p><p>or chest discomfort.</p><p>&bull; Low blood pressure</p><p>&bull; Kidney failure.</p><p>&bull; Abdominal pain and constipation which may be a sign of abnormal</p><p>dilatation of the large intestines which may lead to death</p><p>&bull; Abdominal pain which could be a sign of breakdown of part of the intestine</p><p>due to its compromised blood supply which may lead to death</p><p>&bull; Abdominal pain with fever and/or constipation or bloody diarrhoea as</p><p>possible signs of potentially life-threatening bowel disease</p><p>&bull; Muscle spasms, fever, red-brown urine which could be possible signs of</p><p>abnormal breakdown of muscles (rhabdomyolysis)</p><p>&bull; Varying degrees of pain in the chest and the abdomen which may be a</p><p>sign of inflammation of the membranes simultaneously in several body</p><p>cavities such as those in the chest, abdomen and joints.</p><p>&bull; Liver disorders including fatty liver disease, death</p><p>of liver cells, liver toxicity/injury.</p><p>&bull; Liver disorders that involve replacement of normal liver tissue with scar</p><p>tissue leading to loss of liver function, including those liver events leading</p><p>to life-threatening consequences such as liver failure (which may lead to</p><p>death), liver injury (injury of liver cells, bile duct in the liver, or both) and</p><p>liver transplant.</p><p>&bull; Proven or strongly suspected infection along with fever or low body</p><p>temperature, abnormally rapid breathing, rapid heart rate, change in</p><p>responsiveness and awareness, drop in blood pressure (sepsis).</p><p>&bull; Pauses in breathing or periods of shallow breathing during sleep</p><p>&bull; Allergic reaction (swelling mainly of the face, mouth and throat, as well as,</p><p>the tongue, which may be itchy or painful).</p><p>&bull; Extensive skin rash with fever.</p><p>If you experience or observe any of these, <strong>tell your doctor immediately.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Some side effects are very common</strong></p><p><em>These side effects may affect more than 10 in every 100 patients</em></p><p>&bull; Drowsiness</p><p>&bull; Dizziness</p><p>&bull; Constipation, tell your doctor if constipation gets worse.</p><p>&bull; Increased production of saliva</p><p><strong>&nbsp;</strong></p><p><strong>Some side effects are common</strong></p><p><em>These side effects may affect between 1 and 10 in every 100 patients</em></p><p>&bull; Weight gain</p><p>&bull; Slurred speech</p><p>&bull; Abnormal movements, inability to initiate movement, inability to remain</p><p>motionless, inner feeling restlessness, stiff limbs, trembling hands.</p><p>&bull; Shaking/trembling</p><p>&bull; Muscle stiffness</p><p>&bull; Headache</p><p>&bull; Blurred vision, difficulties in reading</p><p>&bull; Changes in ECG heart machine</p><p>&bull; Light-headedness upon standing due to decreasedblood pressure</p><p>&bull; High blood pressure</p><p>&bull; Nausea, vomiting, dry mouth</p><p>&bull; Elevated liver enzymes</p><p>&bull; Problems in passing or retaining urine</p><p>&bull; Fever</p><p>&bull; Tiredness</p><p><strong>&nbsp;</strong></p><p><strong>Some side effects are uncommon</strong></p><p><em>These side effects may affect between 1 and 10 in every 1,000 patients</em></p><p>&bull; Stuttering in speech</p><p><strong>&nbsp;</strong></p><p><strong>Some side effects are rare</strong></p><p>These side effects may affect between 1 and 10 in every 10,000 patients</p><p>&bull; Excessive thirst, dry mouth and passing large amounts of urine may be</p><p>signs of high sugar levels in the blood (diabetes). If you experience any of</p><p>these, <strong>tell your doctor as soon as possible </strong>as Leponex may cause or</p><p>worsen diabetes.</p><p>&bull; Confusion</p><p>&bull; Irregular heartbeat</p><p>&bull; Difficulty swallowing</p><p>&bull; Increased muscle enzymes</p><p><strong>&nbsp;</strong></p><p><strong>Some side effects are very rare</strong></p><p><em>These side effects may affect less than 1 in every 10,000 patients</em></p><p>&bull; High cholesterol</p><p>&bull; High fatty acids in the blood</p><p>&bull; Involuntary Purposeless movement such as grimacing, lip-smacking,</p><p>rapid eye blinking</p><p>&bull; compulsive thoughts and behaviours</p><p>&bull; Swelling of the glands in the cheeks</p><p>&bull; Skin reactions</p><p><strong>&nbsp;</strong></p><p><strong>Some other side effects may also occur, but their frequency is not known</strong></p><p>&bull; Changes in brain waves machine</p><p>(Electroencephalogram/EEG)</p><p>&bull; Diarrhea</p><p>&bull; Stomach discomfort, heartburn, stomach discomfort after a meal</p><p>&bull; Muscle weakness</p><p>&bull; Muscle spasms</p><p>&bull; Muscle pain</p><p>&bull; Stuffy nose</p><p>&bull; Nocturnal bedwetting</p><p>&bull; Rash, purplish-red spots, fever or itching due to inflammation of blood vessel</p><p>&bull; Inflammation of the colon resulting in diarrhoea,abdominal pain, fever</p><p>&bull; Change in skin colour</p><p>&bull; &ldquo;Butterfly&rdquo; facial rash, joint pain, muscle pain, fever and fatigue (lupus</p><p>erythematous)</p><p>&bull; Sudden, uncontrollable increase in blood pressure</p><p>(pseudophaeochromocytoma)</p><p>&bull; Uncontrolled bending of the body to one side (pleurothotonus)</p><p>&bull; Becoming excessively overweight (bodyweight is at least 20% higher than</p><p>it should be).</p><p>&bull; If you are a male, ejaculatory disorder in which semen enters the bladder</p><p>instead of ejaculating through the penis (dry orgasm or retrograde ejaculation)</p><p>&bull; A strong urge to move the legs (restless legs syndrome) accompanied by</p><p>an unpleasant feeling in the legs</p><p>Contact your doctor if any of these affect you severely. If you notice any side</p><p>effects not mentioned in this leaflet, inform your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep Leponex out of the reach and sight of children.</p><p>&bull; Store in the original package.</p><p>&bull; Do not use Leponex after the expiry date shown on the pack.</p><p>&bull; Do not use any Leponex pack that is damaged or shows signs of tampering.</p><p>&bull; Do not store Leponex above 30&deg;C.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance of Leponex is clozapine.</p><p>&bull; The other inactive ingredients are magnesium stearate, silica, colloidal</p><p>anhydrous, povidone, talc, maize starch, and lactose monohydrate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Leponex is supplied as tablet in packs containing 50 tablets.
Each tablet contains 25 mg or 100 mg clozapine. The scored tablets can be
divided into equal halves.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Mylan Pharma GmbH</p><p>Turmstrasse 24, 6312 Steinhausen,</p><p>Switzerland</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturer</strong></p><p>Madaus GmbH</p><p>L&uuml;tticher Stra&szlig;e 5</p><p>53842 Troisdorf, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in Jun-2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&nbsp;</p><p dir="RTL">1 . ما ھو عقار لیبونكس؟ وفیم یستخدم؟</p><p dir="RTL">ما ھو عقار لیبونكس؟</p><p dir="RTL">یحتوي عقار لیبونكس أقراص على مادة فعالة تُسمى كلوزابین. ینتمي ھذا</p><p dir="RTL">الدَّواء إلى مجموعة من الأدویة تسمى مضادات الذھان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">فیم یستخدم عقار لیبونكس؟</p><p dir="RTL">یستخدم عقار لیبونكس لعلاج الأشخاص الذین یعانون من الفُصَام ممن جربوا</p><p dir="RTL">أدویة أخرى مضادة للذھان ولم تُجد معھم بدرجة كافیة أو لم یتحملوا الأدویة</p><p dir="RTL">الأخرى المضادة للذھان بسبب آثارھا الجانبیة.</p><p dir="RTL">یستخدم عقار لیبونكس لعلاج الأشخاص الذین یعانون من الفُصَام أو اضطراب</p><p dir="RTL">فصامي عاطفي (الفُصَام المصحوب باضطرابات مزاجیة) ممن یحاولون الانتحار بأي شكل من</p><p dir="RTL">الأشكال.</p><p dir="RTL">الفُصَام عبارة عن مرض عقلي ینطوي على اضطرابات في التفكیر وردود الفعل العاطفیة والسلوك.</p><p dir="RTL">بالإضافة إلى ذلك، یستخدم عقار لیبونكس لعلاج اضطرابات التفكیر</p><p dir="RTL">والاضطرابات النفسیة والسلوكیة لدى المرضى الذین یعانون من مرض الشلل الرعَّاش (مرض</p><p dir="RTL">باركنسون) ولم یُجد معھم العلاج القیاسي. ویُعد مرض الشلل الرعَّاش (مرض باركنسون) اضطرابًا</p><p dir="RTL">مزمنًا (مستمرًّا) بالمخ. وھو یُؤثر بشكل أساسي على الطریقة التي ینسق بھا المخ حركات العضلات في أجزاء مختلفة بالجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كیف یعمل عقار لیبونكس؟</strong></p><p dir="RTL">&nbsp;یعمل عقار لیبونكس في الغالب من خلال الارتباط بمستقبل 4D (أو مستقبل</p><p dir="RTL">الدُّوبامِین) الموجود في المخ وإحصاره. ویتسم عقار لیبونكس أیضًا بنشاطھ الضعیف في الارتباط</p><p dir="RTL">والإحصارفي مستقبلات 1Dو 2D ،3Dو 4 D في المخ بالإضافة إلى مستقبلات أخرى یحتمل أن</p><p dir="RTL">تساھم إلى حد ما في فعالیتھهز</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المراقبة أثناء العلاج بعقار لیبونكس</strong></p><p dir="RTL">سیطلب منك إجراء اختبارات دم بصورة منتظمة طیلة مدة استمرارك في</p><p dir="RTL">تناول عقار لیبونكس ولمدة أربعة أسابیع بعد إیقاف العلاج. وسیخبرك طبیبك</p><p dir="RTL">بالوقت الذي یجب علیك فیه إجراء الاختبارات. <strong>ومن المھم أن تجري جمیع</strong></p><p dir="RTL"><strong>اختبارات الدَّم التي یطلبھا منك الطبیب</strong><strong>.</strong></p><p dir="RTL">إذا كنت تعاني من ارتفاع مستوى السُّكَّرِ في الدَّم (مرض السُّكَّرِي) فربما</p><p dir="RTL">یفحص الطبیب مستوى السكر في الدَّم لدیك. وربما یسبب العلاج بعقار</p><p dir="RTL">لیبونكس تغییرًا في دھون الدَّم. وربما یسبب أیضًا عقار لیبونكس زیادة في</p><p dir="RTL">الوزن. لذا قد یراقب طبیبك وزنك ومستویات الدھون في الدم لدیك. إذا كانت</p><p dir="RTL">لدیك أیة أسئلة حول كیفیة عمل عقار لیبونكس أو لماذا تم وصف ھذا الدواء</p><p dir="RTL">لك، فاستشر طبیبك</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا یجب تناول عقار لیبونكس إِ لا إذا وصفه طبیب.</p><p dir="RTL">اتبع جمیع تعلیمات الطبیب بعنایة، حتى إذا كانت تختلف عن المعلومات</p><p dir="RTL">العامة الواردة في ھذه النشرة.</p><p dir="RTL">قبل بدء العلاج بعقار لیبونكس، یتعین أن تجري اختبار دم؛ لتتأكد من أنه</p><p dir="RTL">بإمكانك تناول ھذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تتناول عقار لیبونكس</strong></p><p dir="RTL"><strong>&bull;</strong><strong> </strong><strong>إذا كنت تعاني من حساسیة </strong>تجاه كلوزابین أو أيٍّ من مكونات عقار</p><p dir="RTL">لیبونكس المذكورة في نھایة ھذه النشرة.</p><p dir="RTL"><strong>&bull;</strong><strong> </strong><strong>إذا كنت </strong>غیر قادر على إجراء اختبارات الدَّم بشكل منتظم.</p><p dir="RTL"><strong>&bull;</strong><strong> </strong><strong>إذا كان قد تم </strong>ذات مرة تشخیص حالتك بأنك تعاني من انخفاض عدد</p><p dir="RTL">خلایا الدَّم البیضاء إِ لَّ إذا كان ذلك إثر تناول علاج للسرطان.</p><p dir="RTL"><strong>&bull;</strong><strong> </strong><strong>إذا كنت تعاني </strong>حالیًا أو سابقًا من مرض بالنخاع العظمي.</p><p dir="RTL"><strong>&bull;</strong><strong> </strong><strong>إذا كنت تُعاني </strong>من مشاكل بالكبد أو الكُلى أو القلب.</p><p dir="RTL"><strong>&bull;</strong><strong> </strong><strong>إذا كنت تعاني </strong>من نوبات تشنج خارجة عن السیطرة.</p><p dir="RTL"><strong>&bull;</strong><strong> </strong><strong>إذا كنت تعاني </strong>من مشاكل تتمثل في سوء استخدام العقاقیر أو تعاطي</p><p dir="RTL">الكحولیات.</p><p dir="RTL"><strong>&bull;</strong><strong> </strong><strong>إذا كنت تعاني أو قد عانیت من قبل من </strong>إمساك شدید، انسداد الأمعاء أو</p><p dir="RTL">أي حالة مرضیة أخرى كانت قد أثرت على الأمعاء الغلیظة لدیك.</p><p dir="RTL">إذا كان أيٌّ مما سبق ینطبق علیك، یرجى إبلاغ طبیبك قبل تناول عقار</p><p dir="RTL"><strong>لیبونكس/ كلوزاریل</strong><strong>.</strong></p><p dir="RTL">إذا كنت تعتقد أنك تعاني من حساسیة تجاه عقار لیبونكس (كلوزابین(،</p><p dir="RTL">فاستشر طبیبك أولً قبل تناول عقار لیبونكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توخي حذر خاص مع عقار لیبونكس</strong></p><p dir="RTL">&bull; <strong>إذا كنت قد عانیت </strong>من سكتة دماغیة أو مرض بالقلب أو لدیك تاریخ</p><p dir="RTL">&nbsp;&nbsp;&nbsp;عائلي من الإصابة بتوصیل غیر طبیعي في القلب یسمى &quot;إطالة فترة&ldquo;QT</p><p dir="RTL">&bull; إذا كنت تعاني من تضخم البروستاتا، التشنجات، الجلوكوما &quot;المیاه الزرقاء&quot;</p><p dir="RTL">(حالة مرضیة یكون فیھا ضغط السوائل بالعین مرتفعًا جدًّا عامةً)، مرض</p><p dir="RTL">السُّكَّرِيّ أو أي حالة مرضیة خطیرة أخرى.</p><p dir="RTL">إذا انطبق علیك أي مما سبق، <strong>فأخبر طبیبك قبل تناوُل عقار لیبونكس</strong><strong>.</strong></p><p dir="RTL">&bull; <strong>استشر الطبیب فورًا </strong>عند ظھور أول علامة من علامات البرد، الأنفلونزا،</p><p dir="RTL">الحمى، التھاب الحلق، أو أي عدوى أخرى. قد یؤدي عقار لیبونكس إلى</p><p dir="RTL">انخفاض عدد كرات الدَّم البیضاء فى دمكِ وتؤدي إلى زیادة الحساسیة</p><p dir="RTL">للعدوى. قد یفحص الطبیب عدد خلایا الدم لدیك ویتخذ تدابیر إضافیة إذا</p><p dir="RTL">لزم الأمر.</p><p dir="RTL"><strong>&bull;</strong><strong> </strong><strong>استشر الطبیب فورًا إذا كنت تعاني من </strong>تسارع ضربات القلب وعدم</p><p dir="RTL">انتظامھا والذي یستمر أثناء راحتك، والذي یحتمل أن یكون مصحوبًا</p><p dir="RTL">بضیق النفس وتورم القدمین أو الساقین. فقد تحدث ھذه الآثار خاصةً عند بدء</p><p dir="RTL">العلاج وقد یحتاج الطبیب إلى اتخاذ تدابیر إضافیة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ربما تعاني أثناء العلاج بعقار لیبونكس من</p><p dir="RTL">&bull; شعور بخفة الرأس أو إغماء، خاصةً عند بدء العلاج. وھذا بسبب انخفاض</p><p dir="RTL">ضغط الدَّم.</p><p dir="RTL">&bull; نوبات التشنُّج، نعاس، إغماء، ضعف العضلات، مما قد یؤدي إلى السقوط.</p><p dir="RTL">&bull; ألم في الصدر قد یكون عرضًا لنوبة قلبیة وربما یؤدي إلى الوفاة.</p><p dir="RTL">&bull; ألم في الصدر قد یكون ناجمًا عن التھاب عضلة القلب وربما یؤدي إلى الوفاة.</p><p dir="RTL">&bull; ألم في البطن وإمساك، قد یكون علامة على توسع غیر طبیعي بالأمعاء</p><p dir="RTL">الغلیظة وربما یؤدي إلى الوفاة.</p><p dir="RTL">&bull; ألم في البطن قد یكون علامة على تكسر جزء من الأمعاء بسبب ضعف</p><p dir="RTL">تزوده بالدَّم وربما یؤدي إلى الوفاة.</p><p dir="RTL">&bull; النعاس والبقاء في الفراش لفترة طویلة مع زیادة الوزن مما قد یتسبب في</p><p dir="RTL">إصابة بعض المرضى بتجلط دموي.</p><p dir="RTL">اذا أصبت بأيٍّ مما سبق، <strong>فأخبر طبیبك فورًا</strong><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تناوُل أدویة أخرى</strong></p><p dir="RTL">أخبر الطبیب أو الصیدلي الخاص بك إذا كنت تتناول أو كنت قد تناولت مؤخرًا</p><p dir="RTL">أیَّة أدویة أخرى. ولا تنس تلك التي حصلت علیھا دون وصفة طبیب.</p><p dir="RTL">وھي تشمل الحبوب المنومة، المھدئات، الأدویة المضادة للحساسیة،</p><p dir="RTL">المضادات الحیویة، الأدویة التي تُستخدم لعلاج الاكتئاب، التشنجات أو القرح</p><p dir="RTL">بالمعدة، والأدویة الفعالة ضد العدوى الفیروسیة أو الفطریة، الأدویة الأخرى</p><p dir="RTL">التي تستخدم لعلاج الأمراض العقلیة، أقراص منع الحمل.</p><p dir="RTL">یمكن أن تتداخل ھذه الأدویة مع علاجك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام عقار لیبونكس مع الأغذیة والمشروبات</strong></p><p dir="RTL">&bull; التَّداخل مع الكحولیات: قد یعزز عقار لیبونكس آثار الكحولیات. لا تشرب</p><p dir="RTL">الكحولیات أثناء تناول عقار لیبونكس.</p><p dir="RTL">&bull; یمكن أن تتأثر مستویات عقار لیبونكس في الدَّم بالتَّوقف عن التدخین أو</p><p dir="RTL">تغییر عدد المشروبات التي تحتوي على الكافین التي تتناولھا في الیوم.</p><p dir="RTL">أخبر الطبیب بأي تغییرات في عاداتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كبار السن (بعمر </strong><strong>60 </strong><strong>عامًا فأكبر)</strong></p><p dir="RTL">قد یحتاج الطبیب إلى ضبط علاجك إذا كنت تبلغ من العمر 60 عامًا أو أكبر.</p><p dir="RTL">أخبر طبیبك أو الصیدلي الخاص بك إذا كنت تعاني من حالة مرضیة تسمى</p><p dir="RTL">الخرف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراھقون</strong></p><p dir="RTL">لا یُوصى باستخدام عقار لیبونكس للأطفال والمراھقین.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبیعیة</strong></p><p dir="RTL"><strong>استشیري طبیبكِ أو الصیدلي </strong>قبل استخدام عقار لیبونكس إذا كنتِ حاملً،</p><p dir="RTL">أو تعتقدین أنكِ قد تكونین حاملً. فسیناقش معكِ طبیبكِ الفوائد المرجوة</p><p dir="RTL">والمخاطر المُحتملة لاستخدام ھذا الدواء أثناء فترة الحمل.</p><p dir="RTL"><strong>یجب علیكِ إخبار طبیبكِ فورًا </strong>إذا أصبحتِ حاملً أثناء فترة العلاج بعقار</p><p dir="RTL">لیبونكس. یُعد الأطفال حدیثو الولادة الذین تتناول أمھاتھم عقاقیر مضادة</p><p dir="RTL">للذھان خلال الثلث الأخیر من الحمل معرضین بشكل زائد لخطر الإصابة</p><p dir="RTL">بتصلب الأطراف، الارتجاف، الھِیاج، تصلب العضلات، ترھل (ارتخاء) العضلات، النعاس، قصر</p><p dir="RTL">النفس وضحالته، واضطرابات التغذیة بعد الولادة. وتزول ھذه الأعراض تلقائیًّا لدى بعض الحالات،</p><p dir="RTL">ولكن في حالات أخرى قد یلزم إدخال الأطفال وحدة عنایة مركزة؛ لتقدیم الدعم لھم أو إیداعھم</p><p dir="RTL">المستشفى. <strong>أخبري طبیبكِ أو الصیدلي الخاص بكِ </strong>إذا كنتِ ترضعین طفلكِ طبیعیًّا. قد یفرز <strong>الكلوزابین،</strong></p><p dir="RTL">وھو المادة الفعالة في عقار لیبونكس/كلوزاریل، في لبن الثدي ویُؤثر على الطفل. لذا یجب علیكِ</p><p dir="RTL">الامتناع عن الإرضاع الطبیعي أثناء فترة العلاج بعقار لیبونكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>السیدات ممن لدیھن القدرة على الحمل ووسائل منع الحمل</strong></p><p dir="RTL">تكون دورات الحیض غیر منتظمة أو منعدمة لدى بعض السیدات ممن</p><p dir="RTL">یتناولون أدویة مضادة للذھان. لذا إذا كنت من الإناث اللاتي تأثرن بھذه</p><p dir="RTL">الطریقة، فاعلمي أن دورات الحیض ربما تأتیك ثانیة عندما یتغیر الدَّواء إلى</p><p dir="RTL">عقار لیبونكس. وفي ھذه الحالات، یجب أن تتأكدي من استخدام وسیلة</p><p dir="RTL">موثوقة لمنع حمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الخصوبة</strong><strong>:</strong></p><p dir="RTL">البیانات المتاحة محدودة عن تأثیرات كلوزابین على خصوبة الإنسان فھي غیر حاسمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القیادة واستخدام الآلات</strong></p><p dir="RTL">قد یسبب العلاج بعقار لیبونكس النعاس، خاصة عند بدء العلاج. لذا، یجب</p><p dir="RTL">عدم القیادة أو استخدام الآلات حتى تعتاد على الدَّواء ویزول النعاس.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">یُرجى اتباع تعلیمات طبیبك بعنایة. لا تتجاوز الجرعة الموصى بھا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما ھي الكمیة التي یجب أن تتناولھا من عقار لیبونكس؟</strong></p><p dir="RTL">سیخبرك طبیبك بالضبط كم عدد الأقراص التي ستتناولھا من عقار لیبونكس</p><p dir="RTL">ومعدل تناوُل الأقراص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&bull;</strong><strong> </strong><strong>علاج الفُصَام أو الاضطرابات الفصامیة العاطفیة لدى الأشخاص الذین</strong></p><p dir="RTL"><strong>یحاولون الانتحار بأي شكل من الأشكال</strong></p><p dir="RTL">یبدأ العلاج عادة بنصف قرص 25 مجم ( 12.5 مجم) مرة واحدة أو مرتین</p><p dir="RTL">في أول یوم. وسیقوم طبیبك بعد ذلك بزیادة الجرعة تدریجیًّا، حتى تصل</p><p dir="RTL">إلى الجرعة التي تناسب حالتك بأفضل شكل.</p><p dir="RTL">سیستمر علاجك بجرعة یومیة من عقار لیبونكس تتراوح بین 300 و 450</p><p dir="RTL">مجم. ویتم تناول الجرعة الیومیة عادة على جزأین متساویین، الجزء الأول</p><p dir="RTL">صباحًا والثَّاني عند النوم. وقد یحتاج بعض المرضى إلى جرعات تصل</p><p dir="RTL">بأقصى حد لھا إلى 900 مجم في الیوم.</p><p dir="RTL"><strong>&bull;</strong><strong> </strong><strong>علاج اضطرابات التفكیر والاضطرابات النفسیة والسلوكیة لدى المرضى</strong></p><p dir="RTL"><strong>الذین یعانون من مرض الشلل الرعَّاش (مرض باركنسون)</strong></p><p dir="RTL">یبدأ العلاج عادة بنصف قرص 25 مجم ( 12.5 مجم) في المساء، ثم ستزید</p><p dir="RTL">الجرعة تدریجیًّا حتى تصل إلى الجرعة التي تناسب حالتك بأفضل شكل.</p><p dir="RTL">سیستمر علاجك بجرعة یومیة من عقار لیبونكس تتراوح بین 25 و 37.5</p><p dir="RTL">مجم، وستعطى عادة على ھیئة جرعة واحدة كل مساء.</p><p dir="RTL">قد یحتاج بعض المرضى إلى جرعات تصل إلى 50 مجم في الیوم. وفي</p><p dir="RTL">حالات استثنائیة، قد یصف الطبیب جرعة أعلى ولكنھا لا تتجاوز بأي حال</p><p dir="RTL">من الأحوال 100 مجم في الیوم.</p><p dir="RTL">سیتم قیاس ضغط الدَّم لدیك خلال الأسابیع الأولى من العلاج.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>متى تتناول عقار لیبونكس؟</strong></p><p dir="RTL">تناوُل عقار لیبونكس في الوقت نفسه من كل یوم سیُساعدك على تذكُّر موعد</p><p dir="RTL">تناوُل القرص.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>كیفیة تناول عقار لیبونكس</strong></p><p dir="RTL">ینبغي تناول عقار لیبونكس أقراص عن طریق الفم.</p><p dir="RTL">یمكن تقسیم الأقراص إلى نصفین متساویین (قد یختلف الشكل الصیدلي في</p><p dir="RTL">بعض البلدان).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المدة اللازمة لتناول عقار لیبونكس</strong></p><p dir="RTL">ینبغي الاستمرار في تناول عقار لیبونكس طیلة المدة التي یحددھا طبیبك.</p><p dir="RTL">إذا كانت لدیك أیة استفسارات حول طول المدة اللازمة لتناول عقار لیبونكس,</p><p dir="RTL">فیرجى استشارة الطبیب أو الصیدلي الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت كمیة من عقار لیبونكس أكثر مما یجب (جرعة زائدة)</strong></p><p dir="RTL">إذا كنت قد تناولت كمیة كبیرة جدًّا من الأقراص بطریق الخطأ، <strong>فتحدَّث إلى</strong></p><p dir="RTL"><strong>طبیبك أو الصیدلي الخاص بك على الفور. </strong>فقد تحتاج إلى الرعایة الطبیة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا أغفلت تناوُل عقار لیبونكس</strong></p><p dir="RTL">إذا نسیت تناول جرعة، فتناول جرعة أخرى بمجرد أن تتذكر. ومع ذلك، إذا</p><p dir="RTL">كان وقت الجرعة التَّالیة قد حان، أو كان متبقیًا على وقتھا أقل من 4 ساعات،</p><p dir="RTL">فتجاوز الأقراص الفائتة وتناول جرعتك التَّالیة في الوقت المعتاد.</p><p dir="RTL">لا تستخدم جرعة مضاعفة من عقار لیبونكس لتعویض الجرعة التي أغفلتھا.</p><p dir="RTL">إذا لم تكن قد تناولت عقار لیبونكس لأكثر من یومین، فلا تستأنف تناول</p><p dir="RTL">الدَّواء واتصل بالطبیب بأسرع ما یمكن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول عقار لیبونكس</strong></p><p dir="RTL"><strong>خطر الإصابة بآثار الانسحاب</strong></p><p dir="RTL"><strong>لا تتوقف فجأة عن استخدام عقار لیبونكس</strong><strong>.</strong></p><p dir="RTL">إذا استلزم الأمر التوقف عن تناول ھذا الدَّواء لأي سبب من الأسباب، فسیقوم</p><p dir="RTL">طبیبك بتقلیل الجرعة تدریجیًّا على مدار أسبوع إلى أسبوعین تفادیًا لحدوث</p><p dir="RTL">آثار جانبیة. فالتَّوقف فجأة عن تناول عقار لیبونكس أو تخفیض الجرعة بسرعة</p><p dir="RTL">من شأنھ أن یسبب آثارًا جانبیة.</p><p dir="RTL">لھذا السبب، من المھم للغایة، أن تتمكن أنت ومن یعتني بك من التعرف على</p><p dir="RTL">علامات انسحاب عقار لیبونكس من الجسم.</p><p dir="RTL">إذا كان الإیقاف المفاجئ عن تناول عقار لیبونكس أمرًا ضروریًّا، فربما یعاني</p><p dir="RTL">المریض من أعراض الذھان وأعراض الانسحاب من الجسم مثل: زیادة التعرق،</p><p dir="RTL">والصداع، والغثیان، والقيء، تضیّق قصبي والإسھال.</p><p dir="RTL"><strong>اذا أصبت بأيٍّ من العلامات السابقة، فأخبر طبیبك فورًا. ربما تكون ھذه</strong></p><p><strong>العلامات متبوعة بآثار جانبیة أكثر خطورة إذا لم تعالج فورًا.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أخبر طبیبك أو الصیدلي في أسرع وقت ممكن إذا عانیت من أي أعراض غیر</p><p dir="RTL">متوقعة أثناء استخدامك لعقار لیبونكس، حتى إذا لم تكن تعتقد بأن لھا صلة</p><p dir="RTL">بتناول الدَّواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>بعض الآثار الجانبیة قد تكون خطیرة وتحتاج إلى عنایة طبیة فوریة</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة جدًّا: قد تُؤثر في أكثر من 10 في كل 100 مریض.</p><p dir="RTL">تسارع ضربات القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة: قد تُؤثر ھذه الآثار الجانبیة في ما بین 1 و 10 في كل 100 مریض.</p><p dir="RTL">&bull; <strong>علامات حدوث عدوى </strong>مثل: الحُمى أو الرعشة الشدیدة أو التھاب الحلق</p><p dir="RTL">أو قُرح الفم. قد یُؤدي عقار لیبونكس إلى انخفاض عدد كرات الدَّم البیضاء</p><p dir="RTL">في دمك ویؤدي إلى زیادة الحساسیة للعدوى.</p><p dir="RTL">&bull; نوبات تشنجیة.</p><p dir="RTL">&bull; ارتفاع مستوى نوع معین من خلایا الدَّم البیضاء، زیادة عدد خلایا الدَّم البیضاء.</p><p dir="RTL">&bull; فقدان الوعي (الغیبوبة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">غیر شائعة: قد تُؤثر في ما بین 1 و 10 في كل 1000 مریض.</p><p dir="RTL">&bull; حمى، تقلصات عضلیة، تذبذب في ضغط الدَّم، تَوَھان، ارتباك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادرة: قد تُؤثر في ما بین 1 و 10 في كل 10000 مریض</p><p dir="RTL">&bull; انخفاض شدید في ضغط الدَّم.</p><p dir="RTL">&bull; ألم في الصدر ناجم عن التھاب عضلة القلب.</p><p dir="RTL">&bull; ألم في الصدر ناجم عن التھاب البطانة الخارجیة للقلب.</p><p dir="RTL">&bull; تجلط الدَّم.</p><p dir="RTL">&bull; انخفاض مستوى خلایا الدَّم الحمراء.</p><p dir="RTL">&bull; دخول الطعام إلى الرئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&bull;</strong><strong> </strong><strong>علامات على وجود عدوى بالجھاز التنفسي أو الالتھاب الرئوي </strong>مثل:</p><p dir="RTL">الحمى، السعال، صعوبة التَّنفس، الأزیز بالصدر.</p><p dir="RTL">&bull; ألم بالبطن ناتج عن التھاب البنكریاس.</p><p dir="RTL">&bull; اصفرار بالجلد والعینین، غثیان، و/ أو فقدان الشھیة، بول ذو لون داكن</p><p dir="RTL">علامة على اضطرابات الكبد، التھاب الكبد.</p><p dir="RTL">نادرة جدًّا: قد تُؤثر في أقل من 1 في كل 10,000 مریض.</p><p dir="RTL">&bull; نزیف تلقائي أو علامات كدمات محتملة تشیر إلى انخفاض عدد صفائح الدَّم.</p><p dir="RTL">&bull; ارتفاع مستویات الصفائح في الدَّم.</p><p dir="RTL">&bull; توھان/ ارتباك، غثیان/ قيء، تبول زائد، ألم بالبطن مصحوب بارتفاع</p><p dir="RTL">مستوى السكر في الدَّم.</p><p dir="RTL">&bull; ألم في الصدر، عدم انتظام ضربات القلب وفشل القلب.</p><p dir="RTL">&bull; ضیق التنفس وضحالته.</p><p dir="RTL">&bull; الشعور بالإعیاء، القيء المصحوب بإمساك شدید/ مطول.</p><p dir="RTL">&bull; اصفرار البشرة نتیجة الإصابة بالتھاب شدید بالكبد، ألم بالبطن.</p><p dir="RTL">&bull; التھاب الكُلى.</p><p dir="RTL">&bull; انتصاب العضو الذكري لمدة طویلة.</p><p dir="RTL">&bull; وفاة مفاجئة غیر معروفة الأسباب.</p><p dir="RTL">&bull; مشاكل في وظائف الكلى.</p><p dir="RTL">نسبة التكرار غیر معروفة: الآثار الجانبیة التَّالیة ربما تحدث أیضًا، ولكن معدل</p><p dir="RTL">تكرارھا غیر معروف</p><p dir="RTL">&bull; زیادة التَّعرق، الصداع، الغثیان، القيء والإسھال (أعراض متلازمة الفعل</p><p dir="RTL">الكولیني).</p><p dir="RTL">&bull; السقوط نتیجة نوبات التشنج الناجمة عن العلاج بعقار لیبونكس، النعاس،</p><p dir="RTL">الإغماء، ضعف العضلات.</p><p dir="RTL">&bull; ألم في الصدر قد یكون عرضًا لنوبة قلبیة وربما یؤدي إلى الوفاة.</p><p dir="RTL">&bull; ألم في الصدر قد یكون علامة على التھاب عضلة القلب وربما یؤدي إلى</p><p dir="RTL">الوفاة.</p><p dir="RTL">&bull; ألم ساحق في الصدر (علامات على عدم تدفق الدَّم والأكسجین إلى عضلة</p><p dir="RTL">القلب بشكل كافٍ(.</p><p dir="RTL">&bull; ألم في الصدر، سُعال، فُواق، تسارع التنفس (علامات على تجمع السوائل</p><p dir="RTL">بین طبقات الأنسجة التي تبطن تجویف الصدر والرئتین).</p><p dir="RTL">&bull; شعور متقطع ب &quot;الارتطام&quot;، &quot;الطرق&quot;، أو &quot;الرفرفة&quot; في الصدر</p><p dir="RTL">(الخفقان).</p><p dir="RTL">&bull; تسارع ضربات القلب وعدم انتظامھا (رجفان أذیني). وربما یحدث أحیانًا:</p><p dir="RTL">خفقان، إغماء، ضیق في التَّنفس، أو شعور غیر مریح بالصدر.</p><p dir="RTL">&bull; انخفاض ضغط الدَّم.</p><p dir="RTL">&bull; الفشل الكُلوي.</p><p dir="RTL">&bull; ألم في البطن وإمساك، قد یكون علامة على توسع غیر طبیعي بالأمعاء</p><p dir="RTL">الغلیظة وربما یؤدي إلى الوفاة.</p><p dir="RTL">&bull; ألم في البطن قد یكون علامة على تكسر جزء من الأمعاء بسبب ضعف</p><p dir="RTL">تزوده بالدَّم وربما یؤدي إلى الوفاة.</p><p dir="RTL">&bull; ألم بالبطن مصحوب بحمى و/أو إمساك أو إسھال دموي كأعراض محتملة</p><p dir="RTL">لمرض معوي قد یكون مھدداً للحیاة.</p><p dir="RTL">&bull; تقلصات عضلیة، حمى، تبول بول أحمر یمیل إلى البني وقد تكون ھذه</p><p dir="RTL">علامات على انحلال غیر طبیعي بالعضلات (انحلال الربیدات(.</p><p dir="RTL">&bull; درجات متفاوتة من الألم في الصدر والبطن قد تكون علامة على التھاب</p><p dir="RTL">الأغشیة بشكل متزامن في تجاویف كثیرة بالجسم مثل تلك الموجودة في</p><p dir="RTL">الصدر والبطن والمفاصل.</p><p dir="RTL">&bull; اضطرابات في الكبد تشمل مرض الكبد الدھني، موت خلایا الكبد، إصابة/</p><p dir="RTL">تسمم الكبد.</p><p dir="RTL">&bull; اضطرابات في الكبد تنطوي على استبدل نسیج الكبد الطبیعي بنسیج به ندبات مما</p><p dir="RTL">یؤدي إلى فقدان الكبد لوظائفه، بما في ذلك أعراضٌ كبدیة لھا عواقب مھددة للحیاة</p><p dir="RTL">مثل الفشل الكبدي (الذي قد یُؤدي إلى الوفاة)،</p><p dir="RTL">إصابة الكبد (إصابة خلایا الكبد، أو القناة الصفراویة بالكبد أو كلیھما)، وزراعة الكبد.</p><p dir="RTL">&bull; عدوى محققة أو مشتبه بھا بشدة مصحوبة بحمى أو انخفاض درجة حرارة</p><p dir="RTL">الجسم، تسارع التنفس بشكل غیر طبیعي، تسارع ضربات القلب، تغیر في</p><p dir="RTL">الاستجابة والوعي، انخفاض في ضغط الدَّم (تعفن الدم).</p><p dir="RTL">&bull; توقفات في التنفس أو فترات من التنفس الضحل أثناء النوم.</p><p dir="RTL">&bull; تفاعل حساسیة (تورُّم بشكل أساسي في الوجه والفم والحَلْق، بالإضافة إلى</p><p dir="RTL">اللسان، وقد یكون مصحوبًا بحكة أو مؤلمًا(.</p><p dir="RTL">&bull; طفح جلدي مصحوب بحمى</p><p dir="RTL"><strong>أخبر طبیبك فورًا </strong>إذا عانیت من أو لاحظت أیًّا منھا.</p><p dir="RTL">بعض الآثار الجانبیة تكون شائعة جدًّا</p><p dir="RTL">قد تُؤثر على أكثر من 10 في كل 100 مریض.</p><p dir="RTL">&bull; نعاس.</p><p dir="RTL">&bull; دوخة.</p><p dir="RTL">&bull; إمساك، ویجب إخبار الطبیب إذا ساء الإمساك.</p><p dir="RTL">&bull; زیادة إفراز اللعاب.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>بعض الآثار الجانبیة تكون شائعة</strong></p><p dir="RTL">قد تُؤثر ھذه الآثار الجانبیة في ما بین 1 و 10 في كل 100 مریض.</p><p dir="RTL">&bull; زیادة الوزن.</p><p dir="RTL">&bull; تداخل الكلام.</p><p dir="RTL">&bull; حركات غیر طبیعیة، عدم القدرة على بدء الحركة، عدم القدرة على البقاء</p><p dir="RTL">ساكنًا (بلا حركة) شعور داخلي بالتململ (عدم الارتیاح)، تصلب الأطراف،</p><p dir="RTL">ارتجاف الیدین.</p><p dir="RTL">&bull; ارتعاش/ ارتجاف.</p><p dir="RTL">&bull; تصلب العضلات.</p><p dir="RTL">&bull; صداع.</p><p dir="RTL">&bull; عدم وضوح الرؤیة، صعوبات في القراءة.</p><p dir="RTL">&bull; تغییرات في رسم القلب الكھربائي بجھاز القلب.</p><p dir="RTL">&bull; شعور بخفة الرأس عند الوقوف بسبب انخفاض ضغط الدَّم.</p><p dir="RTL">&bull; ارتفاع ضغط الدَّم.</p><p dir="RTL">&bull; غثیان، قيء، جفاف الفم.</p><p dir="RTL">&bull; ارتفاع إنزیمات الكبد.</p><p dir="RTL">&bull; مشاكل في التبول أو إمساك البول.</p><p dir="RTL">&bull; حمّى.</p><p dir="RTL">&bull; تعب.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>بعض الآثار الجانبیة تكون غیر شائعة</strong></p><p dir="RTL">قد تُؤثر في ما بین 1 و 10 في كل 1000 مریض</p><p dir="RTL">&bull; التَلَعثُم في الكلام.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>بعض الآثار الجانبیة تكون شائعة</strong><strong>.</strong></p><p dir="RTL">قد تُؤثر في ما بین 1 و 10 في كل 10000 مریض</p><p dir="RTL">&bull; العطش الزَّائد، جفاف الفم وتبول كمیات كبیرة من البول وقد تكون ھذه</p><p dir="RTL">علامات على ارتفاع مستویات السكر في الدَّم (مرض السُّكَّرِيّ) .</p><p dir="RTL"><strong>أخبر طبیبك بأسرع ما یمكن </strong>إذا عانیت من أيٍّ من ھذه الآثار؛ لأنَّ</p><p dir="RTL">لیبونكس ربما یؤدي إلى الإصابة بمرض السُّكَّرِيّ أو تدھوره.</p><p dir="RTL">&bull; ارتباك.</p><p dir="RTL">&bull; عدم انتظام ضربات القلب.</p><p dir="RTL">&bull; صعوبة البلع.</p><p dir="RTL">&bull; زیادة إنزیمات العضلات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>بعض الآثار الجانبیة تكون شائعة جدًّا</strong></p><p dir="RTL">قد تُؤثر على أقل من 1 في كل 10,000 مریض</p><p dir="RTL">&bull; ارتفاع الكولیسترول.</p><p dir="RTL">&bull; ارتفاع مستوى الأحماض الدھنیة في الدَّم.</p><p dir="RTL">&bull; حركات لا إرادیة بلا ھدف مثل: التجھم، تمطق الشفتین، الرمش بسرعة.</p><p dir="RTL">&bull; أفكار وسلوكیات قھریة.</p><p dir="RTL">&bull; تورُّم الغدد في الخدود.</p><p dir="RTL">&bull; التفاعلات الجلدیة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>بعض الآثار الجانبیة الأخرى ربما تحدث ھي الأخرى، ولكن معدل تكرارھا</strong></p><p dir="RTL"><strong>غیر معروف</strong></p><p dir="RTL">&bull; تغییرات في جھاز قیاس موجات الدماغ (رسم الدماغ الكھربائي).</p><p dir="RTL">&bull; إسھال.</p><p dir="RTL">&bull; اضطراب المعدة، حموضة (حُرْقَةُ الفُؤاد)، اضطراب المعدة بعد الأكل.</p><p dir="RTL">&bull; ضعف العضلات.</p><p dir="RTL">&bull; تقلصات عضلیة.</p><p dir="RTL">&bull; ألم في العضلات.</p><p dir="RTL">&bull; انسداد الأنف.</p><p dir="RTL">&bull; التبول اللیلي اللا إرادي.</p><p dir="RTL">&bull; طفح جلدي، ظھور بقع أرجوانیة، حمى أو حكة ناجمة عن التھاب الأوعیة الدَّمویة.</p><p dir="RTL">&bull; التھاب القولون الذي یؤدي إلى حدوث إسھال، ألم في البطن، حمى.</p><p dir="RTL">&bull; تغییر في لون الجلد.</p><p dir="RTL">&bull; طفح جلدي بالوجه &quot;على شكل الفراشة&quot;، ألم في المفاصل، ألم في</p><p dir="RTL">العضلات، حمى وتعب (الذئبة الحمامیة).</p><p dir="RTL">&bull; ارتفاع مفاجئ في ضغط الدَّم، لا یمكن السیطرة علیھ (ورم القواتم الزائف).</p><p dir="RTL">&bull; انحناء الجسم بشكل لا یمكن التَّحكم فیه إلى أحد الجوانب (التقوس الجانبي).</p><p dir="RTL">&bull; زیادة الوزن بشكل مفرط (كأن یكون وزن الجسم أثقل مما ینبغي بنسبة</p><p dir="RTL">٪20 على الأقل).</p><p dir="RTL">&bull; اضطراب في القذف، لدى الذكور؛ حیث یدخل السائل المنوي المثانة بدلً</p><p dir="RTL">من أن یقذف عبر العضو الذكري (نشوة جنسیة جافة &quot;بدون قذف&quot; أو قذف مرتجع).</p><p dir="RTL">&bull; رغبة قویة في تحریك الساقین (متلازمة تململ الساقین) یرافقه شعور غیر</p><p dir="RTL">مریح في الساقین.</p><p dir="RTL">إذا كان أيٌّ من ھذه الآثار یُؤثر علیك بشدة، فأخبر طبیبك. إذا لاحظت أیة</p><p dir="RTL">آثار جانبیة غیر المذكورة في ھذه النَّشرة، یُرجى إبلاغ الطبیب أو الصیدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;یحفظ عقار لیبونكس بعیدًا عن متناول ورؤیة الأطفال.</p><p dir="RTL">&bull; یحفظ داخل العبوة الأصلیة.</p><p dir="RTL">&bull; لا یُستخدم عقار لیبونكس بعد انتھاء تاریخ الصلاحیة الموضح على العبوة.</p><p dir="RTL">&bull; لا تستخدم عقار لیبونكس إذا كانت العبوة تالفة أو تظھر علیھا علامات العبث.</p><p dir="RTL">&bull; لا تقم بتخزین عقار لیبونكس في درجة حرارة تتعدى 30 درجة مئویة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما ھو عقار لیبونكس؟</strong></p><p dir="RTL"><strong>&bull;</strong><strong> </strong><strong>المادة الفعالة </strong>في عقار لیبونكس ھي كلوزابین.</p><p dir="RTL">&bull; المكونات الأخرى غیر الفعالة ھي: ستیرات الماغنیسیوم، سیلیكا غرویة لا</p><p dir="RTL">مائیة، بوفیدون، تلك، نشا الذرة، لاكتوز أحادي الھیدرات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما ھو شكل عقار لیبونكس؟ وما ھي محتویات العبوة؟</strong></p><p dir="RTL">یتوفر عقار لیبونكس على ھیئة أقراص في عبوة تحتوي على 50 قرصًا.</p><p dir="RTL">یحتوي كل قرص على 25 مجم أو 100 مجم كلوزابین. یمكن تقسیم الأقراص</p><p dir="RTL">إلى نصفین متساویین.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التَّسویق</strong></p><p dir="RTL"><strong>میلان فارما ش.ذ.م.م</strong></p><p dir="RTL"><strong>ترمستراس </strong><strong>24</strong></p><p dir="RTL"><strong>6312 </strong><strong>شتاینھاوسن، سویسرا،</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>جھة التَّصنیع</strong></p><p dir="RTL">ماداوس ذات المسؤولیة المحدودة</p><p dir="RTL">لوتیشار ستاربا 5</p><p dir="RTL">53842 ترویسدورف</p><p dir="RTL">ألمانیا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر مراجعة تمت للنشرة في یونیو – 2021 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Leponex
Antipsychotic agent

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                25 mg Tablet: Each tablet contains 25 mg clozapine. 100 mg Tablet: Each tablet contains 100 mg clozapine.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets. The scored tablets can be divided into equal halves.

Active substance
Clozapine
Certain dosage strengths may not be available in all countries.
 

Active moiety
Clozapine

Excipients
Leponex tablets: magnesium stearate; silica, colloidal anhydrous; povidone; talc; maize starch; lactose monohydrate.
Pharmaceutical formulations may vary between countries.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment-resistant schizophrenia</p><p>Leponex is indicated in patients with treatment-resistant schizophrenia, i.e. patients with schizophrenia who are non-responsive to or intolerant of classic antipsychotics.</p><p><strong>Non-responsiveness </strong>is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two marketed antipsychotics prescribed for adequate durations.</p><p><strong>Intolerance </strong>is defined as the impossibility of achieving adequate clinical benefit with classic antipsychotics because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Risk of recurrent suicidal behavior</p><p>Leponex is indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re- experiencing suicidal behavior, based on history and recent clinical state. Suicidal behavior refers to actions by a patient that put him/herself at high risk for death.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Psychosis during the course of Parkinson&rsquo;s disease</p><p>Leponex is indicated in psychotic disorders occurring during the course of Parkinson&#39;s disease, in cases where standard treatment has failed.</p><p>The failure of standard treatment is defined as the lack of control of the psychotic symptoms and/or the onset of functionally unacceptable motoric deterioration occurring after the following measures have been taken:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withdrawal of anti-cholinergic medication including tricyclic anti-depressants</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Attempt to reduce the dose of antiparkinsonian medication with dopaminergic effect</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dosage information</p><p>The dosage must be adjusted individually. For each patient the lowest effective dose should be used. Cautious titration and a divided dosage schedule are necessary to minimize the risks of hypotension, seizure, and sedation.</p><p>Initiation of Leponex treatment must be restricted to those patients with a WBC count</p><p>&sup3;3500/mm&sup3; (3.5 x 109/L) and an ANC &sup3;2000/mm&sup3; (2.0 x 109/L), and within standardized normal limits.</p><p>Dose adjustment is indicated in patients who are also receiving medicinal products that have pharmacokinetic interactions with clozapine, such as benzodiazepines or selective serotonin re- uptake inhibitors (see section INTERACTIONS).</p><p>&nbsp;</p><p>Method of administration</p><p>Leponex is administered orally.</p><p>&nbsp;</p><p>Switching from a previous antipsychotic therapy to Leponex</p><p>It is generally recommended that Leponex should not be used in combination with other antipsychotics. When Leponex therapy is to be initiated in a patient undergoing oral antipsychotic therapy, it is recommended that the dosage of other antipsychotics be reduced or discontinued by gradually tapering it downwards. Based on the clinical circumstances, the prescribing physician should judge whether or not to discontinue the other antipsychotic therapy before initiating treatment with Leponex.</p><p>&nbsp;</p><p>Treatment resistant schizophrenia</p><p><strong>&nbsp;</strong></p><p><strong>Starting therapy</strong></p><p>Leponex should be started with 12.5 mg (half a 25 mg tablet) once or twice on the first day, followed by one or two 25 mg tablets on the second day. If well tolerated, the daily dose may then be increased slowly in increments of 25 mg to 50 mg in order to achieve a dose level of up to 300 mg/day within 2 to 3 weeks. Thereafter, if required, the daily dose may be further increased in increments of 50 mg to 100 mg at half-weekly or, preferably, weekly intervals.</p><p>&nbsp;</p><p><strong>Therapeutic dose range</strong></p><p>In most patients, antipsychotic efficacy can be expected with 300 to 450 mg/day given in divided doses. Some patients may be treated with lower doses, and some patients may require doses up to 600 mg/day. The total daily dose may be divided unevenly, with the larger portion being taken at bedtime.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Maximum dose</strong></p><p>To obtain full therapeutic benefit, a few patients may require larger doses, in which case judicious increments (not exceeding 100 mg) are permissible up to 900 mg/day. However the possibility of increased adverse reactions (in particular seizures) occurring at doses over 450 mg/day must be borne in mind.</p><p>&nbsp;</p><p><strong>Maintenance dose</strong></p><p>After achieving maximum therapeutic benefit, many patients can be maintained effectively on lower doses. Careful downward titration is therefore recommended. Treatment should be maintained for at least 6 months. If the daily dose does not exceed 200 mg, once daily administration in the evening may be appropriate.</p><p>&nbsp;</p><p><strong>Ending therapy</strong></p><p>In the event of planned termination of Leponex therapy, a gradual reduction in dose over a 1- to 2-week period is recommended. If abrupt discontinuation is necessary (e.g. because of leucopenia), the patient should be carefully observed for the recurrence of psychotic symptoms and symptoms related to cholinergic rebound (see section WARNINGS AND PRECAUTIONS).</p><p>&nbsp;</p><p><strong>Restarting therapy</strong></p><p>In patients in whom the interval since the last dose of Leponex exceeds 2 days, treatment should be re-initiated with 12.5 mg (half a 25-mg tablet) given once or twice on the first day. If this dose is well tolerated, it may be feasible to titrate the dose to the therapeutic level more quickly than is recommended for initial treatment. However, in any patient who has previously experienced respiratory or cardiac arrest with initial dosing (see section WARNINGS AND PRECAUTIONS), but was then able to be successfully titrated to a therapeutic dose, re-titration should be done with extreme caution.</p><p>&nbsp;</p><p>Reducing the risk of suicidal behavior in schizophrenia and schizoaffective disorder</p><p>The dosage and administration recommendations described in the preceding subsection regarding the use of Leponex in patients with treatment-resistant schizophrenia should also be followed when treating patients with schizophrenia or schizoaffective disorder at risk for recurrent suicidal behaviour.</p><p>A course of treatment with Leponex of at least two years is recommended in order to maintain the reduction of risk for suicidal behaviour. It is recommended that the patient&rsquo;s risk of suicidal behaviour be reassessed after two years of treatment and that thereafter the decision to continue treatment with Leponex be re-visited at regular intervals, based on thorough assessments of patient&rsquo;s risk for suicidal behaviour during treatment.</p><p>&nbsp;</p><p>&nbsp;</p><p>Psychotic disorders occurring during the course of Parkinson&#39;s disease, in cases where standard treatment has failed</p><p><strong>&nbsp;</strong></p><p><strong>Starting therapy</strong></p><p>The starting dose must not exceed 12.5 mg/day (half a 25 mg tablet), taken in the evening. Subsequent dose increases must be by 12.5 mg increments, with a maximum of two increments a week up to a maximum of 50 mg, a dose that cannot be reached until the end of the second week. The total daily amount should preferably be given as a single dose in the evening.</p><p>&nbsp;</p><p><strong>Therapeutic dose range</strong></p><p>The mean effective dose is usually between 25 and 37.5 mg/day. In the event that treatment for at least one week with a dose of 50 mg fails to provide a satisfactory therapeutic response, dosage may be cautiously increased by increments of 12.5 mg/week.</p><p>&nbsp;</p><p><strong>Maximum dose</strong></p><p>The dose of 50 mg/day should only be exceeded in exceptional cases, and the maximum dose of 100 mg/day must never be exceeded.</p><p>Dose increases should be limited or deferred if orthostatic hypotension, excessive sedation or confusion occurs. Blood pressure should be monitored during the first weeks of treatment.</p><p>&nbsp;</p><p><strong>Maintenance dose</strong></p><p>When there has been complete remission of psychotic symptoms for at least 2 weeks, an increase in anti-parkinsonian medication is possible if indicated on the basis of motor status. If this approach results in the recurrence of psychotic symptoms, Leponex dosage may be increased by increments of 12.5 mg/week up to a maximum of 100 mg/day, taken in one or two divided doses (see above).</p><p>&nbsp;</p><p><strong>Ending therapy</strong></p><p>When ending therapy, a gradual reduction in dose by steps of 12.5 mg over a period of at least one week (preferably two) is recommended.</p><p>Treatment must be discontinued immediately in the event of neutropenia or agranulocytosis as indicated in section (WARNINGS AND PRECAUTIONS). In this situation, careful psychiatric monitoring of the patient is essential since symptoms may recur quickly.</p><p>&nbsp;</p><p>Special populations</p><p><strong>&nbsp;</strong></p><p><strong>Cardiovascular disorders</strong></p><p>In patients suffering from cardiovascular disorders (note: severe cardiovascular disorders are contraindications) the initial dose should be 12.5 mg given once on the first day, and dosage increase should be slow and in small increments.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Renal impairment</strong></p><p>In patients with mild to moderate renal impairment the initial dose should be 12.5 mg given once on the first day, and dosage increase should be slow and in small increments.</p><p>&nbsp;</p><p><strong>Hepatic impairment</strong></p><p>Patients with hepatic impairment should receive Leponex with caution along with regular monitoring of liver function tests (see section WARNINGS AND PRECAUTIONS).</p><p>&nbsp;</p><p><strong>Pediatrics</strong></p><p>No pediatric studies have been performed. The safety and efficacy of Leponex in children and adolescents have not been established.</p><p>&nbsp;</p><p><strong>Patients 60 years of age and older</strong></p><p>It is recommended that treatment in patients 60 years and older is initiated at a particularly low dose (12.5 mg given once on the first day) with subsequent dose increments restricted to 25 mg/day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Known hypersensitivity to clozapine or to any of the excipients of Leponex.
•	Patients unable to undergo regular blood tests.
•	History of toxic or idiosyncratic granulocytopenia/agranulocytosis (with the exception of granulocytopenia/agranulocytosis from previous chemotherapy).
•	Impaired bone marrow function.
•	Uncontrolled epilepsy.
•	Alcoholic and other toxic psychoses, drug intoxication, comatose conditions.
•	Circulatory collapse and/or CNS depression of any cause.
•	Severe renal or cardiac disorders (e.g. myocarditis).
•	Active liver disease associated with nausea, anorexia or jaundice; progressive liver disease, hepatic failure.
•	Paralytic ileus.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Special precautionary measure</p><p><strong>&nbsp;</strong></p><p><strong>Agranulocytosis</strong></p><p>Because of the association of Leponex with agranulocytosis, the following precautionary measures are mandatory:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drugs known to have a substantial potential to depress bone marrow function should not be used concurrently with Leponex. In addition, the concomitant use of long-acting depot antipsychotics should be avoided because of the impossibility of removing these medications, which may be potentially myelosuppressive, from the body rapidly in situations where this may be required, e.g. granulocytopenia.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with a history of primary bone marrow disorders may be treated only if the benefit outweighs the risk. They should be carefully reviewed by a haematologist prior to starting Leponex.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients who have low white blood cell (WBC) counts because of benign ethnic neutropenia should be given special consideration and may be started on Leponex after agreement of a haematologist.</p><p>Leponex must be dispensed under strict medical supervision in accordance with official recommendations.</p><p>&nbsp;</p><p>White Blood Cell (WBC) counts and Absolute Neutrophil Count (ANC) monitoring</p><p>White blood cell count (WBC) and differential blood counts must be performed within 10 days prior to starting Leponex treatment to ensure that only patients with normal leukocyte (WBC</p><p>&ge;3500/mm3 (&ge;3.5 x 109/L)) and absolute neutrophil counts (ANC &sup3;2000/mm3 (&ge;2.0 x 109/L)) will receive Leponex. After the start of Leponex treatment, regular WBC count and ANC must be performed and monitored weekly for 18 weeks, and thereafter at least every four weeks throughout treatment, and for 4 weeks after complete discontinuation of Leponex.</p><p>Prescribing physicians should comply fully with the required safety measures. At each consultation, the patient should be reminded to contact the treating physician immediately if any kind of infection begins to develop. Particular attention should be paid to flu-like complaints such as, fever or sore throat and to other evidence of infection, which may be indicative of neutropenia. A differential blood count must be performed immediately if any symptoms or signs of an infection occur.</p><p>&nbsp;</p><p>Low WBC count and/or ANC</p><p>If during the first 18 weeks of Leponex therapy, the WBC count falls to between 3500/mm3 and 3000/mm3 and/or the ANC falls to between 2000/mm3 and 1500/mm3, haematological evaluations must be performed at least twice weekly.</p><p>&nbsp;</p><p>&nbsp;</p><p>After 18 weeks of Leponex therapy, haematological evaluations should be performed at least twice weekly if the WBC count falls to between 3000/mm3 and 2500/mm3 and/or the ANC falls to between 1500/mm3 and 1000/mm3.</p><p>In addition, if, during Leponex therapy, the WBC count is found to have dropped by a substantial amount from baseline, a repeat WBC count and a differential blood count should be performed. A substantial drop is defined as a single drop of 3000 mm3 or more in the WBC count or a cumulative drop of 3000 mm3 or more within three weeks.</p><p>Immediate discontinuation of Leponex is mandatory if the WBC count is less than 3000/mm3 or the ANC is less than 1500/mm3 during the first 18 weeks of therapy, or if the WBC count is less than 2500/mm3 or the ANC is less than 1000/mm3 after the first 18 weeks of therapy. WBC counts and differential blood counts should then be performed daily and patients should be carefully monitored for flu-like symptoms or other symptoms suggestive of infection. Following discontinuation of Leponex, haematological evaluation is required until haematological recovery has occurred.</p><p>If Leponex has been withdrawn and WBC count falls further to below 2000/mm3 and/or the ANC falls below 1000/mm3, the management of this condition must be guided by an experienced haematologist. If possible, the patient should be referred to a specialised haematological unit, where protective isolation and the administration of GM-CSF (granulocyte-macrophage colony stimulating factor) or G-CSF (granulocyte colony stimulating factor) may be indicated. It is recommended that the colony stimulating factor therapy be discontinued when the neutrophil count has returned to a level above 1000/mm3.</p><p>Patients in whom Leponex has been discontinued as a result of white blood cell deficiencies (see above) must not be re-exposed to Leponex.</p><p>It is recommended that the haematological values be confirmed by performing two blood counts on two consecutive days; however, Leponex should be discontinued after the first bloodcount.</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:group id="Group_x0020_101" o:spid="_x0000_s2080"
  style='position:absolute;left:0;text-align:left;margin-left:85.1pt;
  margin-top:15.6pt;width:457.1pt;height:.5pt;z-index:-251656192;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1702,312" coordsize="9142,10"
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:line id="Line_x0020_104" o:spid="_x0000_s2081" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1702,317" to="7171,317"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
  <v:rect id="Rectangle_x0020_103" o:spid="_x0000_s2082" style='position:absolute;
   left:7171;top:311;width:10;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:line id="Line_x0020_102" o:spid="_x0000_s2083" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="7181,317" to="10843,317"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".48pt"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="612" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br /><strong>Table 1:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood monitoring during the first 18 weeks of Leponex therapy</strong></p><p>&nbsp;</p><p><strong>Blood cell count&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Action required</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_95" o:spid="_x0000_s2074" style='position:absolute;left:0;
  text-align:left;margin-left:85.1pt;margin-top:14.5pt;width:457.1pt;height:.5pt;
  z-index:-251655168;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1702,290" coordsize="9142,10"
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:line id="Line_x0020_100" o:spid="_x0000_s2075" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1702,295" to="4466,295"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
  <v:rect id="Rectangle_x0020_99" o:spid="_x0000_s2076" style='position:absolute;
   left:4464;top:290;width:12;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:line id="Line_x0020_98" o:spid="_x0000_s2077" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="4476,295" to="7171,295"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight=".48pt"/>
  <v:rect id="Rectangle_x0020_97" o:spid="_x0000_s2078" style='position:absolute;
   left:7171;top:290;width:10;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:line id="Line_x0020_96" o:spid="_x0000_s2079" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="7181,295" to="10843,295"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".48pt"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="612" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br /><strong>WBC/mm&sup3; (/L)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ANC/mm&sup3; (/L)</strong></p><p>&nbsp;</p><p>&sup3;3500 (&ge;3.5 x 109)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &sup3;2000 (&ge;2.0 x 109)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Continue Leponex treatment.</p><p>&nbsp;</p><p>Between &ge;3000 and &lt;3500 (&ge;3.0 x 109 and &lt;3.5 x 109)</p><p>&nbsp;</p><p>Between &ge;1500 and &lt;2000 (&ge;1.5 x 109 and &lt;2.0 x 109)</p><p>&nbsp;</p><p>Continue Leponex treatment, sample blood twice weekly until counts stabilize or increase.</p><p>&nbsp;</p><p>&lt;3000 (&lt;3.0 x 109)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;1500 (&lt;1.5 x 109)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immediately stop Leponex treatment,</p><p>sample blood daily until hematological abnormality is resolved, monitor for infection. Do not re-expose the patient.</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_89" o:spid="_x0000_s2068" style='width:457.8pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="9156,10" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:line id="Line_x0020_94" o:spid="_x0000_s2069" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="0,5" to="2779,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCdBiRWwwAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/JasMw
EL0X8g9iCr01cnNoEjdKaApZwKc4gfY4SFPL1BoZS7Xdv68Cgdzm8dZZbUbXiJ66UHtW8DLNQBBr
b2quFFzOu+cFiBCRDTaeScEfBdisJw8rzI0f+ER9GSuRQjjkqMDG2OZSBm3JYZj6ljhx375zGBPs
Kmk6HFK4a+Qsy16lw5pTg8WWPizpn/LXKegPxVdfzD3qw2extXq3r+fDXqmnx/H9DUSkMd7FN/fR
pPnLGVyfSRfI9T8AAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAnQYkVsMAAADcAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" strokeweight=".48pt"/>
 <v:rect id="Rectangle_x0020_93" o:spid="_x0000_s2070" style='position:absolute;
  left:2764;width:10;height:10;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:line id="Line_x0020_92" o:spid="_x0000_s2071" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="2774,5" to="5484,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
 <v:rect id="Rectangle_x0020_91" o:spid="_x0000_s2072" style='position:absolute;
  left:5469;width:10;height:10;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:line id="Line_x0020_90" o:spid="_x0000_s2073" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="5479,5" to="9156,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="612" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1027" type="#_x0000_t75" style='width:457.8pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_85" o:spid="_x0000_s2064" style='position:absolute;left:0;
  text-align:left;margin-left:85.1pt;margin-top:15.65pt;width:457.1pt;height:.5pt;
  z-index:-251653120;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1702,313" coordsize="9142,10"
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:line id="Line_x0020_88" o:spid="_x0000_s2065" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1702,318" to="7171,318"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQB5N4VhxQAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8Mw
DIXvg/4Ho8Fuq7Md1pLVLVuh7SCntYXuKGw1Do3lEHtJ9u+nw2A3iff03qfVZgqtGqhPTWQDT/MC
FLGNruHawPm0e1yCShnZYRuZDPxQgs16drfC0sWRP2k45lpJCKcSDficu1LrZD0FTPPYEYt2jX3A
LGtfa9fjKOGh1c9F8aIDNiwNHjvaerK343cwMByqr6FaRLSHS/Xu7W7fLMa9MQ/309srqExT/jf/
XX84wV8KrTwjE+j1LwAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQB5N4VhxQAAANwAAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
" strokeweight=".48pt"/>
  <v:rect id="Rectangle_x0020_87" o:spid="_x0000_s2066" style='position:absolute;
   left:7171;top:312;width:10;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:line id="Line_x0020_86" o:spid="_x0000_s2067" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="7181,318" to="10843,318"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="612" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br /><strong>Table 2:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood monitoring after 18 weeks of Leponex therapy</strong></p><p>&nbsp;</p><p><strong>Blood cell count&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Action required</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_79" o:spid="_x0000_s2058" style='position:absolute;left:0;
  text-align:left;margin-left:85.1pt;margin-top:14.5pt;width:457.1pt;height:.5pt;
  z-index:-251652096;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1702,290" coordsize="9142,10"
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:line id="Line_x0020_84" o:spid="_x0000_s2059" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1702,295" to="4466,295"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
  <v:rect id="Rectangle_x0020_83" o:spid="_x0000_s2060" style='position:absolute;
   left:4464;top:290;width:12;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:line id="Line_x0020_82" o:spid="_x0000_s2061" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="4476,295" to="7171,295"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
  <v:rect id="Rectangle_x0020_81" o:spid="_x0000_s2062" style='position:absolute;
   left:7171;top:290;width:10;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:line id="Line_x0020_80" o:spid="_x0000_s2063" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="7181,295" to="10843,295"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".48pt"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="612" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br /><strong>WBC/mm&sup3; (/L)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ANC/mm&sup3; (/L)</strong></p><p>&nbsp;</p><p>&sup3;3000 (&ge;3.0 x 109)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &sup3;1500 (&ge;1.5 x 109)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Continue Leponex treatment.</p><p>&nbsp;</p><p>Between &ge;2500 and &lt;3000 (&ge;2.5 x 109 and &lt;3.0 x 109)</p><p>&nbsp;</p><p>Between &ge;1000 and &lt;1500 (&ge;1.0 x 109 and &lt;1.5 x 109)</p><p>&nbsp;</p><p>Continue Leponex treatment, sample blood twice weekly until counts stabilize or increase.</p><p>&nbsp;</p><p>&nbsp;</p><p>&lt;2500 (&lt;2.5 x 109)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;1000 (&lt;1.0 x 109)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immediately stop Leponex treatment,</p><p>sample blood daily until hematological abnormality is resolved, monitor for infection. Do not re-expose the patient.</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_73" o:spid="_x0000_s2052" style='width:457.8pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="9156,10" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:line id="Line_x0020_78" o:spid="_x0000_s2053" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="0,5" to="2779,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
 <v:rect id="Rectangle_x0020_77" o:spid="_x0000_s2054" style='position:absolute;
  left:2764;width:10;height:10;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:line id="Line_x0020_76" o:spid="_x0000_s2055" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="2774,5" to="5484,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".48pt"/>
 <v:rect id="Rectangle_x0020_75" o:spid="_x0000_s2056" style='position:absolute;
  left:5469;width:10;height:10;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:line id="Line_x0020_74" o:spid="_x0000_s2057" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="5479,5" to="9156,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="612" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:457.8pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p>In the event of interruption of therapy for non-hematological reasons</p><p>Patients who have been on Leponex for more than 18 weeks and have had their treatment interrupted for more than 3 days but less than 4 weeks should have their WBC count and ANC monitored weekly for an additional 6 weeks. If no hematological abnormality occurs, monitoring at intervals not exceeding 4 weeks may be resumed. If Leponex treatment has been interrupted for 4 weeks or longer, weekly monitoring is required for the next 18 weeks of treatment (see section DOSAGE AND ADMINISTRATION).</p><p>&nbsp;</p><p>Other precautions</p><p><strong>&nbsp;</strong></p><p><strong>Eosinophilia</strong></p><p>In the event of eosinophilia, discontinuation of Leponex is recommended if the eosinophil count rises above 3000/mm3. Therapy should be re-started only after the eosinophil count has fallen below 1000/mm3.</p><p><strong>Thrombocytopenia</strong></p><p>In the event of thrombocytopenia, discontinuation of Leponex is recommended if the platelet count falls below 50 000/mm3.</p><p><strong>Cardiovascular disorders</strong></p><p>In patients suffering from cardiovascular disorders (note: severe cardiovascular disorders are contraindications) the initial dose should be 12.5 mg given once on the first day, and dosage increase should be slow and in small increments (see section DOSAGE AND ADMINISTRATION).</p><p><strong>Orthostatic hypotension</strong>, with or without syncope, can occur during Leponex treatment. Rarely (about one case per 3000 Leponex-treated patients), collapse can be profound and may be accompanied by cardiac and/or respiratory arrest. Such events are more likely to occur during initial titration in association with rapid dose escalation; on very rare occasions they occurred even after the first dose. Therefore, patients commencing Leponex treatment require close medical supervision.</p><p><strong>Myocarditis and Cardiomyopathy</strong>, Tachycardia that persists at rest, accompanied by arrhythmias, shortness of breath or signs and symptoms of heart failure, may rarely occur during the first month of treatment and very rarely thereafter. The occurrence of these signs and symptoms necessitates an urgent diagnostic evaluation for myocarditis, especially during the titration period. If the diagnosis of myocarditis is confirmed, Leponex should be discontinued. There have been postmarketing reports of myocarditis including fatal cases. Later in treatment, the same signs and symptoms may very rarely occur and may be linked to cardiomyopathy.</p><p>&nbsp;</p><p>&nbsp;</p><p>Further investigation should be performed and if the diagnosis is confirmed, the treatment should be stopped unless the benefit clearly outweighs the risk to the patient.</p><p>In patients who are diagnosed with cardiomyopathy while on Leponex/Clozaril treatment, there is potential to develop mitral valve incompetence. Mitral valve incompetence has been reported in cases of cardiomyopathy related to Leponex/Clozaril treatment. These cases of mitral valve incompetence reported either mild or moderate mitral regurgitation on two- dimensional echocardiography (2DEcho) (see section ADVERSE DRUG REACTIONS).</p><p>Monitoring of standing and supine blood pressure is necessary during the first weeks of treatment in patients with Parkinson&rsquo;s disease.</p><p>&nbsp;</p><p><strong>Myocardial infarction</strong></p><p>There have been postmarketing reports of myocardial infarction including fatal cases. Causality assessment was difficult in the majority of these cases because of serious pre-existing cardiac disease and plausible alternative causes.</p><p>&nbsp;</p><p><strong>QT interval prolongation</strong></p><p>As with other antipsychotics, caution is advised in patients with known cardiovascular disease or family history of QT prolongation.</p><p>As with other antipsychotics, caution should be exercised when Leponex is prescribed with medicines known to increase the QTc interval.</p><p>&nbsp;</p><p><strong>Cerebrovascular adverse events</strong></p><p>An increased risk of cerebrovascular adverse events has been seen in the dementia population with some atypical antipsychotics. The mechanism for this increased risk is not known. An increased risk cannot be excluded for other antipsychotics or other patient populations. Leponex should be used with caution in patients with risk factors for stroke.</p><p>&nbsp;</p><p><strong>Risk of thromboembolism</strong></p><p>Since Leponex may cause sedation and weight gain, thereby increasing the risk of</p><p><strong>thromboembolism</strong>, immobilization of patients should be avoided.</p><p>&nbsp;</p><p><strong>Metabolic changes</strong></p><p>Atypical antipsychotic drugs, including Leponex, have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes may include hyperglycemia, dyslipidemia, and body weight gain. While atypical antipsychotic drugs may produce some metabolic changes, each drug in the class has its own specific risk profile.</p><p>&nbsp;</p><p><strong>Hyperglycemia</strong></p><p>On rare occasions, severe hyperglycemia, sometimes leading to ketoacidosis/hyperosmolar coma, has been reported during Leponex treatment in patients with no prior history of hyperglycemia. While a causal relationship to Leponex use has not been definitely established,</p><p>&nbsp;</p><p>&nbsp;</p><p>glucose levels returned to normal in most patients after discontinuation of Leponex, and re- challenge produced a recurrence of hyperglycemia in a few cases. The effect of Leponex on glucose metabolism in patients with diabetes mellitus has not been studied. Impaired glucose tolerance, severe hyperglycemia, ketoacidosis and hyperosmolar coma have been reported in patients with no prior history of hyperglycemia. Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Exacerbation should be considered in patients receiving Leponex who develop symptoms of hyperglycemia, such as polydipsia, polyuria, polyphagia or weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. In patients with significant treatment-emergent hyperglycemia, discontinuation of Leponex should be considered.</p><p>There is a risk of altering the metabolic balance resulting in slight impairment of glucose homeostasis and a possibility of unmasking a pre-diabetic condition or aggravating pre-existing diabetes.</p><p>&nbsp;</p><p><strong>Dyslipidemia</strong></p><p>Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics, including Leponex. Clinical monitoring, including baseline and periodic follow- up lipid evaluations in patients using clozapine, is recommended.</p><p>&nbsp;</p><p><strong>Weight gain</strong></p><p>Weight gain has been observed with atypical antipsychotic use, including Leponex. Clinical monitoring of weight is recommended.</p><p>&nbsp;</p><p><strong>Seizures</strong></p><p>Leponex may lower seizure threshold. In patients with a history of seizures the initial dose should be 12.5 mg given once on the first day, and dosage increase should be slow and in small increments (see section DOSAGE AND ADMINISTRATION).</p><p>&nbsp;</p><p><strong>Anticholinergic effects</strong></p><p>Clozapine exerts anticholinergic activity, which may produce undesirable effects throughout the body. Careful supervision is indicated in the presence of prostatic enlargement and narrow- angle glaucoma. Probably on account of its anticholinergic properties, Leponex has been associated with varying degrees of impairment of intestinal peristalsis, ranging from constipation to intestinal obstruction, fecal impaction, paralytic ileus, megacolon and intestinal infarction/ischaemia (see section ADVERSE DRUG REACTIONS). On rare occasions these cases have proved fatal.</p><p>&nbsp;</p><p>To avoid complications, careful monitoring during treatment with Leponex is recommended for the early detection of incipient constipation, followed by effective treatment of such constipation.</p><p>Particular caution is necessary in patients with a history of colonic disease or a history of lower abdominal surgery, receiving concomitant medications known to cause constipation (especially those with anticholinergic properties, e.g. various antipsychotic agents, antidepressants and antiparkinsonian agents), as these may exacerbate the situation. It is vital that constipation be recognised and actively treated.</p><p>Special precautions should be observed when considering co-administration with benzodiazepines (or other centrally-acting drugs; see &ldquo;Interactions&rdquo;).</p><p>&nbsp;</p><p><strong>Fever</strong></p><p>During Leponex therapy, patients may experience transient temperature elevations above 38&deg;C, with the peak incidence within the first 3 weeks of treatment. This fever is generally benign. Occasionally, it may be associated with an increase or decrease in the WBC count. Patients with fever should be carefully evaluated to rule out the possibility of an underlying infection or the development of agranulocytosis. In the presence of high fever, the possibility of neuroleptic malignant syndrome (NMS) must be considered. If the diagnosis of NMS is confirmed, Leponex should be discontinued immediately and appropriate medical measures should be administered.</p><p>&nbsp;</p><p>Falls</p><p>Leponex may cause seizures, somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy.</p><p>&nbsp;</p><p>Special populations</p><p><strong>&nbsp;</strong></p><p><strong>Hepatic impairment</strong></p><p>Patients with stable pre-existing liver disorders may receive Leponex, but must undergo regular liver function tests. Such tests should be performed immediately in patients who develop symptoms of possible liver dysfunction such as nausea, vomiting and/or anorexia during Leponex treatment. If the elevation of the values is clinically relevant or if symptoms of jaundice occur, treatment with Leponex must be discontinued. It may be resumed (see section DOSAGE AND ADMINISTRATION - Re-starting therapy) only when the results of liver function tests are normal. In such cases, liver function should be closely monitored after re- introduction of Leponex.</p><p>&nbsp;</p><p>Renal impairment</p><p>In patients suffering from mild to moderate renal impairment, an initial dose of 12.5 mg/day (half a 25 mg tablet) is recommended (see section DOSAGE AND ADMINISTRATION).</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_71" o:spid="_x0000_s2050" style='width:456.25pt;height:.75pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="9125,15" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
">
 <v:line id="Line_x0020_72" o:spid="_x0000_s2051" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="0,7" to="9125,7"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight=".72pt"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="610" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:456.25pt;height:.75pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>Patients aged 60 years and older</p><p>It is recommended that treatment be initiated at a particularly low dose (12.5 mg given once on the first day) and subsequent dose increments be restricted to 25 mg/day.</p><p>Clinical studies with Leponex did not include sufficient numbers of subjects aged 60 years and over to determine whether or not they respond differently from younger subjects.</p><p>Orthostatic hypotension can occur with Leponex treatment and there have been rare reports of tachycardia, which may be sustained, in patients taking Leponex. Patients aged 60 years and older, particularly those with compromised cardiovascular function, may be more susceptible to these effects.</p><p>Patients aged 60 years and older may also be particularly susceptible to the anticholinergic effects of clozapine, such as urinary retention and constipation.</p><p>&nbsp;</p><p>Patients aged 60 years and older with Dementia-related Psychosis</p><p>In patients aged 60 years and older with dementia-related psychosis, the efficacy and safety of clozapine has not been studied. Observational studies suggest that patients aged 60 years and older with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. In the published literature, risk factors that may predispose this patient population to increased risk of death when treated with antipsychotics include sedation, the presence of cardiac conditions (e.g. cardiac arrhythmias) or pulmonary conditions (e.g. pneumonia, with or without aspiration). Leponex should be used with caution in patients aged 60 years and older with dementia.</p><p>&nbsp;</p><p>Rebound, withdrawal effects</p><p>If abrupt discontinuation of Leponex is necessary (e.g. because of leucopenia), the patient should be carefully observed for the recurrence of psychotic symptoms and symptoms related to cholinergic rebound such as profuse sweating, headache, nausea, vomiting and diarrhoea.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacodynamic-related interactions</p><p><strong>&nbsp;</strong></p><p><strong>Anticipated pharmacodynamic interactions resulting in concomitant use not being recommended</strong></p><p>Medicinal products known to have a substantial potential to depress bone marrow function should not be used concurrently with Leponex (see section WARNINGS AND PRECAUTIONS).</p><p>As with other antipsychotics, caution should be exercised when Leponex is prescribed with medicines known to increase the QTc interval, or causing electrolyte imbalance.</p><p>&nbsp;</p><p><strong>Observed pharmacodynamic interactions to be considered</strong></p><p>Particular caution is recommended when Leponex therapy is initiated in patients who are receiving (or have recently received) a benzodiazepine or any other psychotropic agent, as these patients may have an increased risk of circulatory collapse, which, on rare occasions, can be profound and may lead to cardiac and/or respiratory arrest.</p><p>Concomitant use of lithium or other CNS-active agents may increase the risk of development of neuroleptic malignant syndrome (NMS).</p><p>&nbsp;</p><p>&nbsp;</p><p>Rare but serious reports of seizures, including onset of seizures in non-epileptic patients, and isolated cases of delirium where Leponex was co-administered with valproic acid have been reported. These effects are possibly due to a pharmacodynamic interaction, the mechanism of which has not been determined.</p><p>&nbsp;</p><p><strong>Anticipated pharmacodynamic interactions to be considered</strong></p><p>Clozapine may enhance the central effects of alcohol, MAO inhibitors and CNS depressants such as narcotics, antihistamines, and benzodiazepines.</p><p>Because of the possibility of additive effects, caution is essential when substances possessing anticholinergic, hypotensive, or respiratory depressant effects are given concomitantly.</p><p>Owing to its anti-alpha-adrenergic properties, clozapine may reduce the blood pressure- increasing effect of norepinephrine or other predominantly alpha-adrenergic agents and reverse the pressor effect of epinephrine.</p><p>&nbsp;</p><p>Pharmacokinetic-related interactions</p><p>Clozapine is a substrate for many CYP 450 isoenzymes, in particular 1A2 and 3A4. The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized. Nevertheless, caution is called for in patients receiving concomitant treatment with other substances that are either inhibitors or inducers of these enzymes.</p><p>No clinically relevant interactions have been observed thus far with tricyclic antidepressants, phenothiazines or type 1C anti-arrhythmics, which are known to bind to cytochrome P450 2D6.</p><p>&nbsp;</p><p><strong>Observed pharmacokinetic interactions to be considered</strong></p><p>Concomitant administration of substances known to induce cytochrome P450 enzymes may decrease the plasma levels of clozapine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Substances known to induce the activity of 3A4 and with reported interactions with clozapine include, for instance, carbamazepine, phenytoin and rifampicin.</p><p>Concomitant administration of substances known to inhibit the activity of cytochrome P450 isozymes may increase the plasma levels of clozapine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Substances known to inhibit the activity of the major isozymes involved in the metabolism of clozapine and with reported interactions include, for instance, cimetidine, erythromycin (3A4), fluvoxamine (1A2), perazine (1A2), ciprofloxacin (1A2) and oral contraceptives (1A2, 3A4, 2C19).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The plasma concentration of clozapine is increased by caffeine (1A2) intake and decreased by nearly 50% following a 5-day caffeine-free period.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated clozapine plasma concentrations also have been reported in patients receiving the substances in combination with selective serotonin re-uptake inhibitors (SSRIs) such as paroxetine (1A2), sertraline, fluoxetine or citalopram.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Anticipated pharmacokinetic interactions to be considered</strong></p><p>Concomitant administration of substances known to induce cytochrome P450 enzymes may decrease the plasma levels of clozapine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Known inducers of 1A2 include, for instance, omeprazole and tobacco smoke. In cases of sudden cessation of tobacco smoking, the plasma clozapine concentration may be increased, thus leading to an increase in adverse effects.</p><p>Concomitant administration of substances known to inhibit the activity of cytochrome P450 isozymes may increase the plasma levels of clozapine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Potent inhibitors of CYP3A, such as azole antimycotics and protease inhibitors, could potentially also increase clozapine plasma concentrations; no interactions have been reported to date, however.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of child-bearing potential and contraceptive measures</p><p>Some female patients treated with antipsychotics other than Leponex may become amenorrheic. A return to normal menstruation may occur as a result of switching from other antipsychotics to Leponex. Adequate contraceptive measures must therefore be ensured in women of childbearing potential.</p><p>&nbsp;</p><p>Pregnancy</p><p>Reproduction studies in animals have revealed no evidence of impaired fertility or harm to the fetus due to clozapine. However, the safe use of Leponex in pregnant women has not been established. Therefore, Leponex should be used in pregnancy only if the expected benefit clearly outweighs any potential risk.</p><p>&nbsp;</p><p><strong>Non-teratogenic effects</strong></p><p>Neonates exposed to antipsychotic drugs, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization.</p><p>Antipsychotic drugs, including Leponex, should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p><p>&nbsp;</p><p>Breast-feeding</p><p>Animal studies suggest that clozapine is excreted in breast milk and has an effect in the suckling offspring. Therefore, mothers receiving Leponex should not breast-feed.</p><p>&nbsp;</p><p><strong>Fertility:</strong></p><p>Limited data available on the effects of clozapine on human fertility are inconclusive. In male and female rats, clozapine did not affect fertility when administered up to 40 mg/kg, corresponding to a human equivalence dose of 6.4 mg/kg or approximately a third of the maximum permissible adult human dose.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:line id="Line_x0020_70" o:spid="_x0000_s2050"
 style='position:absolute;z-index:251667456;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:page;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page' from="42.35pt,205.9pt" to="42.35pt,228.6pt"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" strokeweight=".72pt">
 <w:wrap anchorx="page" anchory="page"/>
</v:line><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Owing to the ability of Leponex to cause sedation and lower the seizure threshold, activities such as driving or operating machinery should be avoided, especially during the initial weeks of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile</p><p>The adverse effects of clozapine are most often predictable based on its pharmacological properties with the exception of agranulocytosis (see section WARNINGS AND PRECAUTIONS).</p><p>The most serious adverse reactions experienced with clozapine are agranulocytosis, seizure, cardiovascular effects and fever (see section WARNINGS AND PRECAUTIONS). The most common side effects are drowsiness/sedation, dizziness, tachycardia, constipation, and hypersalivation.</p><p>Data from the clinical trials experience showed that a varying proportion of clozapine-treated patients (from 7.1 to 15.6%) were discontinued due to an adverse event, including only those that could be reasonably attributed to clozapine. The more common events considered to be causes of discontinuation were leukopenia; somnolence; dizziness (excluding vertigo); and psychotic disorder.</p><p>Adverse drug reactions (ADRs) are listed by MedDRA system organ class (see Table 3). Within each system organ class, the adverse reactions are ranked by frequency, using the following convention: Very common (&sup3;1/10), common (&sup3;1/100, &lt;1/10), uncommon (&sup3;1/1,000, &lt;1/100), rare (&sup3;1/10,000, &lt;1/1,000), very rare (&lt;1/10,000), including isolated reports. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:shape id="Freeform_x0020_69"
  o:spid="_x0000_s2112" style='position:absolute;left:0;text-align:left;
  margin-left:90.5pt;margin-top:33.15pt;width:453.6pt;height:.1pt;z-index:-251648000;
  visibility:visible;mso-wrap-style:square;mso-width-percent:0;
  mso-height-percent:0;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
  mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
  mso-height-relative:page;v-text-anchor:top' coordsize="9072,1270" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
" path="m,l9072,e" filled="f" strokeweight=".48pt">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;5760720,0"
   o:connectangles="0,0"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="606" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br /><strong>Table 3:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment-Emergent Adverse Experience Frequency estimate from Spontaneous and Clinical Trial Reports</strong></p><p>&nbsp;</p><p><strong>Blood and lymphatic system disorders</strong></p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leukopenia/decreased WBC/neutropenia, eosinophilia, leukocytosis</p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Agranulocytosis</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia, Lymphopenia.</p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombocytopenia, thrombocythemia, thrombocytosis</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_65" o:spid="_x0000_s2108" style='width:453.6pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="9072,10" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:line id="Line_x0020_68" o:spid="_x0000_s2109" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="0,5" to="3970,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
 <v:rect id="Rectangle_x0020_67" o:spid="_x0000_s2110" style='position:absolute;
  left:3969;width:10;height:10;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:line id="Line_x0020_66" o:spid="_x0000_s2111" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="3979,5" to="9072,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".48pt"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="607" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1034" type="#_x0000_t75" style='width:453.6pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><strong>Metabolism and nutrition disorders</strong></p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight gain</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes aggravated impaired glucose tolerance, new onset diabetes</p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyperosmolar coma, ketoacidosis, severe hyperglycemia, hypercholesterolemia, hypertriglyceridemia</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_61" o:spid="_x0000_s2104" style='width:453.6pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="9072,10" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:line id="Line_x0020_64" o:spid="_x0000_s2105" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="0,5" to="3970,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
 <v:rect id="Rectangle_x0020_63" o:spid="_x0000_s2106" style='position:absolute;
  left:3969;width:10;height:10;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:line id="Line_x0020_62" o:spid="_x0000_s2107" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="3979,5" to="9072,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDX6FJywgAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9Na8JA
EL0L/odlhN50Uw9RUldpBbWQk7bQHofdaTY0Oxuy2yT9964geJvH+5zNbnSN6KkLtWcFz4sMBLH2
puZKwefHYb4GESKywcYzKfinALvtdLLBwviBz9RfYiVSCIcCFdgY20LKoC05DAvfEifux3cOY4Jd
JU2HQwp3jVxmWS4d1pwaLLa0t6R/L39OQX8qv/ty5VGfvso3qw/HejUclXqaja8vICKN8SG+u99N
mp/ncHsmXSC3VwAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQDX6FJywgAAANwAAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" strokeweight=".48pt"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="607" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1033" type="#_x0000_t75" style='width:453.6pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><strong>Psychiatric disorders</strong></p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dysarthria</p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dysphemia</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Agitation, restlessness</p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Obsessive-compulsive disorders</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_57" o:spid="_x0000_s2100" style='width:453.6pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="9072,10" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:line id="Line_x0020_60" o:spid="_x0000_s2101" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="0,5" to="3970,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
 <v:rect id="Rectangle_x0020_59" o:spid="_x0000_s2102" style='position:absolute;
  left:3969;width:10;height:10;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:line id="Line_x0020_58" o:spid="_x0000_s2103" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="3979,5" to="9072,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="607" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1032" type="#_x0000_t75" style='width:453.6pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><strong>Nervous system disorders</strong></p><p>Very common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drowsiness/sedation, dizziness</p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizures/convulsions/myoclonic jerks, extrapyramidal symptoms, akathisia, tremor, rigidity, headache, rigor</p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neuroleptic malignant syndrome</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confusion, delirium</p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tardive dyskinesia</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_53" o:spid="_x0000_s2096" style='width:453.6pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="9072,10" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:line id="Line_x0020_56" o:spid="_x0000_s2097" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="0,5" to="3970,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
 <v:rect id="Rectangle_x0020_55" o:spid="_x0000_s2098" style='position:absolute;
  left:3969;width:10;height:10;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:line id="Line_x0020_54" o:spid="_x0000_s2099" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="3979,5" to="9072,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="607" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1031" type="#_x0000_t75" style='width:453.6pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><strong>Eye disorders</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_49" o:spid="_x0000_s2092" style='position:absolute;left:0;
  text-align:left;margin-left:90.5pt;margin-top:14.5pt;width:453.6pt;height:.5pt;
  z-index:-251642880;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1810,290" coordsize="9072,10"
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:line id="Line_x0020_52" o:spid="_x0000_s2093" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1810,295" to="5779,295"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
  <v:rect id="Rectangle_x0020_51" o:spid="_x0000_s2094" style='position:absolute;
   left:5779;top:290;width:10;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:line id="Line_x0020_50" o:spid="_x0000_s2095" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="5789,295" to="10882,295"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight=".48pt"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="606" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br />Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blurred vision</p><p>&nbsp;</p><p><strong>Cardiac disorders</strong></p><p>Very common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tachycardia</p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ECG changes</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Circulatory collapse, arrhythmias, myocarditis, pericarditis</p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_45" o:spid="_x0000_s2088" style='position:absolute;left:0;
  text-align:left;margin-left:90.5pt;margin-top:14.55pt;width:453.6pt;height:.5pt;
  z-index:-251641856;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1810,291" coordsize="9072,10"
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:line id="Line_x0020_48" o:spid="_x0000_s2089" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1810,296" to="5779,296"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
  <v:rect id="Rectangle_x0020_47" o:spid="_x0000_s2090" style='position:absolute;
   left:5779;top:291;width:10;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:line id="Line_x0020_46" o:spid="_x0000_s2091" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="5789,296" to="10882,296"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="606" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br />Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiac arrest, Cardiomyopathy</p><p>&nbsp;</p><p><strong>Vascular disorders</strong></p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Syncope, orthostatic hypotension, postural hypotension, hypertension,</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thromboembolism</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_41" o:spid="_x0000_s2084" style='width:453.6pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="9072,10" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEA8VGOoboDAAB6CwAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsVstu4zYU3RfoPxDcK5JsSbaEUQaJ
H0GBtA3GMx/ASLQllCJVkn616L/3kpRs2ZkEQYrZNYuINMnLew/POeSnz4eGoR2VqhY8x+FNgBHl
hShrvsnxt69Lb4qR0oSXhAlOc3ykCn++/fmnTyTbSNJWdYEgAlcZyXGldZv5vioq2hB1I1rKYWwt
ZEM0dOXGLyXZQ+SG+aMgSPyG1BzfnkPNiSZoK+sPhGKi+IOWM8J3REFIVmTDX7ocWfHfI5OM7x5k
u2qfpMm8+G33JFFd5hiQ46QBiLDfDXTToOtfrdqcAxzWsjHzxXqNDjbK0fy3MehBowJ+jCdJMBnB
BgWMJeO4Gy6q37+zqKgWby2DVNyW0BikYZsmj1eqC6NxX9+DFNsWReF1nWa1DfMIZ6Fc1QDPQ1/r
KyCg5/2vogTcyFYLy4YfCEkKODoYQwviK2gUB75qHRoz07w+6zCKejQea04RdPtDH843Sy0YiItZ
RfiGrirS0q/HFsq1+MH+ANFpjYXo1COZgp3fiU98SZlxOun4clknyVqp9AMVDTKNHDPI36JOdo9K
u1Prp1gExLJmzFbHONoD/4I0sQuUYHVpBs00JTfPMybRjjCgr/0zCUFBF9OAOry0wSpKykXX1qRm
rg3zGTfxgPqQTtdynvB3GqSL6WIaedEoWXhRMJ97d8tZ5CXLcBLPx/PZbB7+Y1ILo6yqy5Jyk13v
T2H0QvxNXUihxFrfFKLxQYF1QXuPAocKg7ND8R4G/zK6LRGS7b82aVO15Qw0ip5KqiPU99gU92z6
Qgsw2w0DSo1PlOpXqCsy3Ukp9gZHdcEmNx225rvzynfwaJwmKUYv3QeUYo3nSjEvmCQh97eYdEGE
d/LFkWEA/lv0CEdRcD9KvWUynXjRMoo9EMHUC8L0Pk2CKI3my0t6WO1219fH6WFEkcaj+MOiaGpN
JWJ1k+PpSTkke00hJ3ab9Hve9d9L/pFMH5yR6cO9KI9GT8/wBTZIAeKHk4W7HxqVkH9htIcbPcfq
zy2RFCP2CwdipeB1ME3bThTba0gOR56HI4QXECrHGiPXnGnowfptK+tNBTuFFiYu7sDt13VnOC4n
kx1TeqWPjFqPsIqhvHwiknyBnBlII8eUe99WnbnADCD6ubitoqvWiMh5j6veytEEP2mRny13eIWH
UdIL0dn66KTBgSnbKD/e1sHBnRyvnD0OUriKzUvgf2d3L8+PS9eQYmAuJ2W5Ww148w5nh1nd48m/
enVabnavZPO0HfZv/wUAAP//AwBQSwMEFAAGAAgAAAAhAOFRNx/PBgAA5hsAABoAAABjbGlwYm9h
cmQvdGhlbWUvdGhlbWUxLnhtbOxZzW/cRBS/I/E/jHxvs9/NRt1U2c1uA23aKNkW9Thrz9rTjD3W
zGzSvaH2iISEKIgDlbhxQEClVuJS/ppAERSp/wJvZmyvJ+uQtI2gguaQtZ9/877fm6/LV+7FDB0Q
ISlPel79Ys1DJPF5QJOw590ajy6sekgqnASY8YT0vDmR3pX199+7jNd8RtMJxyIYRyQmCBglcg33
vEipdG1lRfpAxvIiT0kC36ZcxFjBqwhXAoEPQUDMVhq1WmclxjTx1oGj0oyGDP4lSmqCz8SeZkNQ
gmOQfnM6pT4x2GC/rhFyLgdMoAPMeh7wDPjhmNxTHmJYKvjQ82rmz1tZv7yC17JBTJ0wtjRuZP6y
cdmAYL9hZIpwUgitj1rdS5sFfwNgahk3HA4Hw3rBzwCw74OlVpcyz9Zotd7PeZZA9nGZ96DWrrVc
fIl/c0nnbr/fb3czXSxTA7KPrSX8aq3T2mg4eAOy+PYSvtXfGAw6Dt6ALL6zhB9d6nZaLt6AIkaT
/SW0DuholHEvIFPOtirhqwBfrWXwBQqyocguLWLKE3VSrsX4LhcjAGggw4omSM1TMsU+5OQAxxNB
sRaA1wgufbEkXy6RtCwkfUFT1fM+THHilSAvn33/8tkTdHT/6dH9n44ePDi6/6Nl5IzawklYHvXi
28/+fPQx+uPJNy8eflGNl2X8rz988svPn1cDoXwW5j3/8vFvTx8//+rT3797WAHfEHhSho9pTCS6
QQ7RLo/BMOMVV3MyEa82YhxhWh6xkYQSJ1hLqeA/VJGDvjHHLIuOo0efuB68LaB9VAGvzu46Cu9F
YqZoheRrUewAtzlnfS4qvXBNyyq5eTxLwmrhYlbG7WJ8UCV7gBMnvsNZCn0zT0vH8EFEHDV3GE4U
DklCFNLf+D4hFdbdodTx6zb1BZd8qtAdivqYVrpkTCdONi0GbdEY4jKvshni7fhm+zbqc1Zl9SY5
cJFQFZhVKD8mzHHjVTxTOK5iOcYxKzv8OlZRlZJ7c+GXcUOpINIhYRwNAyJl1ZibAuwtBf0aho5V
GfZtNo9dpFB0v4rndcx5GbnJ9wcRjtMq7B5NojL2A7kPKYrRDldV8G3uVoh+hzjg5MRw36bECffp
3eAWDR2VFgmiv8yEjiW0aqcDxzT5u3bMKPRjmwPn146hAT7/+lFFZr2tjXgD5qSqStg61n5Pwh1v
ugMuAvr299xNPEt2CKT58sTzruW+a7nef77lnlTPZ220i94KbVevG+yi2CyR4xNXyFPK2J6aM3Jd
mkWyhHkiGAFRjzM7QVLsmNIIHrO+7uBCgc0YJLj6iKpoL8IpLLDrnmYSyox1KFHKJWzsDLmSt8bD
Il3ZbWFbbxhsP5BYbfPAkpuanO8LCjZmtgnN5jMX1NQMziqseSljCma/jrC6VurM0upGNdPqHGmF
yRDDZdOAWHgTFiAIli3g5Q7sxbVo2JhgRgLtdzv35mExUTjPEMkIBySLkbZ7OUZ1E6Q8V8xJAORO
RYz0Ju8Ur5WkdTXbN5B2liCVxbVOEJdH702ilGfwIkq6bo+VI0vKxckSdNjzuu1G20M+TnveFPa0
8BinEHWp13yYhXAa5Cth0/7UYjZVvohmNzfMLYI6HFNYvy8Z7PSBVEi1iWVkU8N8ylKAJVqS1b/R
BreelwE2019Di+YqJMO/pgX40Q0tmU6Jr8rBLlG07+xr1kr5TBGxFwWHaMJmYhdD+HWqgj0BlXA0
YTqCfoFzNO1t88ltzlnRlU+vDM7SMUsjnLVbXaJ5JVu4qeNCB/NWUg9sq9TdGPfqppiSPydTymn8
PzNFzydwUtAMdAR8OJQVGOl67XlcqIhDF0oj6o8ELBxM74BsgbNY+AxJBSfI5leQA/1ra87yMGUN
Gz61S0MkKMxHKhKE7EBbMtl3CrN6NndZlixjZDKqpK5MrdoTckDYWPfAjp7bPRRBqptukrUBgzue
f+57VkGTUC9yyvXm9JBi7rU18E+vfGwxg1FuHzYLmtz/hYoVs6odb4bnc2/ZEP1hscxq5VUBwkpT
QTcr+9dU4RWnWtuxlixutHPlIIrLFgOxWBClcN6D9D+Y/6jwmb1t0BPqmO9Cb0Vw0aCZQdpAVl+w
Cw+kG6QlTmDhZIk2mTQr69ps6aS9lk/W57zSLeQec7bW7CzxfkVnF4szV5xTi+fp7MzDjq8t7URX
Q2SPlyiQpvlGxgSm6tZpG6doEtZ7Htz8QKDvwRPcHXlAa2haQ9PgCS6EYLFkb3F6XvaQU+C7pRSY
Zk5p5phWTmnllHZOgcVZdl+SUzrQqfQVB1yx6R8P5bcZsILLbj/ypupcza3/BQAA//8DAFBLAwQU
AAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5n
MS54bWwucmVsc4SPzQrCMBCE74LvEPZu0noQkSa9iNCr1AcIyTYtNj8kUezbG+hFQfCyMLPsN7NN
+7IzeWJMk3ccaloBQae8npzhcOsvuyOQlKXTcvYOOSyYoBXbTXPFWeZylMYpJFIoLnEYcw4nxpIa
0cpEfUBXNoOPVuYio2FBqrs0yPZVdWDxkwHii0k6zSF2ugbSL6Ek/2f7YZgUnr16WHT5RwTLpRcW
oIwGMwdKV2edNS1dgYmGff0m3gAAAP//AwBQSwECLQAUAAYACAAAACEAu+VIlAUBAAAeAgAAEwAA
AAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQCtMD/xwQAA
ADIBAAALAAAAAAAAAAAAAAAAADYBAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQDxUY6hugMA
AHoLAAAfAAAAAAAAAAAAAAAAACACAABjbGlwYm9hcmQvZHJhd2luZ3MvZHJhd2luZzEueG1sUEsB
Ai0AFAAGAAgAAAAhAOFRNx/PBgAA5hsAABoAAAAAAAAAAAAAAAAAFwYAAGNsaXBib2FyZC90aGVt
ZS90aGVtZTEueG1sUEsBAi0AFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAAAAAAAAAAAAAAAAHg0A
AGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc1BLBQYAAAAABQAFAGcB
AAAhDgAAAAA=
">
 <v:line id="Line_x0020_44" o:spid="_x0000_s2085" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="0,5" to="3970,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQADwzX+wgAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9LawIx
EL4L/ocwhd40W5EqW6NUQS3syQe0xyGZbpZuJssm3d3++0YQvM3H95zVZnC16KgNlWcFL9MMBLH2
puJSwfWynyxBhIhssPZMCv4owGY9Hq0wN77nE3XnWIoUwiFHBTbGJpcyaEsOw9Q3xIn79q3DmGBb
StNin8JdLWdZ9iodVpwaLDa0s6R/zr9OQXcsvrpi4VEfP4ut1ftDtegPSj0/De9vICIN8SG+uz9M
mj+fw+2ZdIFc/wMAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQADwzX+wgAAANwAAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" strokeweight=".48pt"/>
 <v:rect id="Rectangle_x0020_43" o:spid="_x0000_s2086" style='position:absolute;
  left:3969;width:10;height:10;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:line id="Line_x0020_42" o:spid="_x0000_s2087" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="3979,5" to="9072,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="607" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image007.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1030" type="#_x0000_t75" style='width:453.6pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><strong>Respiratory disorders</strong></p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aspiration of ingested food, pneumonia and lower respiratory tract infection which may be fatal</p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respiratory depression/arrest</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_37" o:spid="_x0000_s2080" style='width:453.6pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="9072,10" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:line id="Line_x0020_40" o:spid="_x0000_s2081" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="0,5" to="3970,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQB8+DP9xQAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9BS8NA
EIXvgv9hmYI3u6mILWm3RYW2Qk62BT0Ou9NsMDsbsmsS/71zELzN8N68981mN4VWDdSnJrKBxbwA
RWyja7g2cDnv71egUkZ22EYmAz+UYLe9vdlg6eLI7zSccq0khFOJBnzOXal1sp4CpnnsiEW7xj5g
lrWvtetxlPDQ6oeieNIBG5YGjx29erJfp+9gYDhWn0O1jGiPH9WLt/tDsxwPxtzNpuc1qExT/jf/
Xb85wX8UfHlGJtDbXwAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQB8+DP9xQAAANwAAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
" strokeweight=".48pt"/>
 <v:rect id="Rectangle_x0020_39" o:spid="_x0000_s2082" style='position:absolute;
  left:3969;width:10;height:10;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:line id="Line_x0020_38" o:spid="_x0000_s2083" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="3979,5" to="9072,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="607" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1029" type="#_x0000_t75" style='width:453.6pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><strong>Gastrointestinal disorders</strong></p><p>Very common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation, hypersalivation</p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea, vomiting, loss of appetite, dry mouth</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dysphagia</p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intestinal obstruction/paralytic ileus/faecal impaction, parotid gland enlargement</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_33" o:spid="_x0000_s2076" style='width:453.6pt;height:.6pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="9072,12" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAVhHXL74DAAB6CwAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsVttu2zgQfV+g/0DwXZFky7IlVCkS
X4IF0m5Qtx/ASLQllCJVkr612H/fISnZstMEQRZ9ax7ioTgczhyeOeT7D/uaoS2VqhI8w+FVgBHl
uSgqvs7w1y8Lb4KR0oQXhAlOM3ygCn+4fvfXe5KuJWnKKkcQgauUZLjUukl9X+UlrYm6Eg3lMLcS
siYahnLtF5LsIHLN/EEQxH5NKo6vT6FmRBO0kdUbQjGRf6PFlPAtURCS5Wn/S5sjy/9/ZJLy7Z1s
ls2DNJnnn7YPElVFhgE5TmqACPvtROsGQ/9i1foUYL+StfEXqxXa2ygH89/GoHuNcvg4GsfBeAAb
5DA3jsFyW5T//GJRXs5fWgapuC3B6KVhTZPHM9WFw1FX350UmwYNh5d1mtU2zD2chXJVAzx3Xa3P
gIAedx9FAbiRjRaWDb8RkgRwdDCGA5P/M2jke75sHBpTY16edTiMOzTuK04RDN2JfNr2/c1SCwbi
YloSvqbLkjT0y6GBcsN2f4DouMZCdByRVMHOr8Rn5DLoKDNMxi1fLFmOdZK0kUrfUVEjY2SYQf4W
dbK9V9pB0rlYBMSiYsxWxzjaZTgOktguUIJVhZk0bkquH6dMoi1hQF/719Z35gbU4YUNVlJSzFtb
k4o5G/Jk3MSDOiCd1nKa8DMJkvlkPom8aBDPvSiYzbybxTTy4kU4Hs2Gs+l0Fv5rUgujtKyKgnKT
XadPYfSk+esql0KJlb7KRe1DB1Y57TQKFCoMTgrFOxj88+iWQpBs92uThirMydlveUcl1RLqV2wa
d2z6THMQ2zUDSrUHCvToVqgLMt1IKXYGR3XGJuduqXRa+QoeDZM4weip+oQtkS465gmTJOT+EpPO
iPBKvjgy9MB/iR7hIApuB4m3iCdjL1pEIw+aYOIFYXKbxEGURLPFOT1s77bX19vpYZoiGQ1Gb26K
utJUIlbVGZ4cO4ekz3XIkd0m/Y533e85/0iq907I9P5WFAfTT4/wC2yQApofThbufjBKIX9gtIMb
PcPq+4ZIihH7mwOxkjCKwE3bQTSy15Dszzz2ZwjPIVSGNUbOnGoYwfpNI6t1CTuFFiYubkDtV1Ur
OC4nkx1TeqkPjFqNsB1DefFAJPkMOTNojQxT7n1dtuICHkD0U3EbRZeNaSInZK56244m+LEX+Uly
+1d4OITXjrvEnaxHTlT7Et1G+f2yDgru2vFC2UdBMnRX2B9ldy/Pt7euIUVPXI6d5W414M0rlB28
2seTf/HqtNxsX8nmadsfX/8HAAD//wMAUEsDBBQABgAIAAAAIQDhUTcfzwYAAOYbAAAaAAAAY2xp
cGJvYXJkL3RoZW1lL3RoZW1lMS54bWzsWc1v3EQUvyPxP4x8b7PfzUbdVNnNbgNt2ijZFvU4a8/a
04w91sxs0r2h9oiEhCiIA5W4cUBApVbiUv6aQBEUqf8Cb2ZsryfrkLSNoILmkLWff/O+35uvy1fu
xQwdECEpT3pe/WLNQyTxeUCTsOfdGo8urHpIKpwEmPGE9Lw5kd6V9fffu4zXfEbTCcciGEckJggY
JXIN97xIqXRtZUX6QMbyIk9JAt+mXMRYwasIVwKBD0FAzFYatVpnJcY08daBo9KMhgz+JUpqgs/E
nmZDUIJjkH5zOqU+Mdhgv64Rci4HTKADzHoe8Az44ZjcUx5iWCr40PNq5s9bWb+8gteyQUydMLY0
bmT+snHZgGC/YWSKcFIIrY9a3UubBX8DYGoZNxwOB8N6wc8AsO+DpVaXMs/WaLXez3mWQPZxmfeg
1q61XHyJf3NJ526/3293M10sUwOyj60l/Gqt09poOHgDsvj2Er7V3xgMOg7egCy+s4QfXep2Wi7e
gCJGk/0ltA7oaJRxLyBTzrYq4asAX61l8AUKsqHILi1iyhN1Uq7F+C4XIwBoIMOKJkjNUzLFPuTk
AMcTQbEWgNcILn2xJF8ukbQsJH1BU9XzPkxx4pUgL599//LZE3R0/+nR/Z+OHjw4uv+jZeSM2sJJ
WB714tvP/nz0MfrjyTcvHn5RjZdl/K8/fPLLz59XA6F8FuY9//Lxb08fP//q09+/e1gB3xB4UoaP
aUwkukEO0S6PwTDjFVdzMhGvNmIcYVoesZGEEidYS6ngP1SRg74xxyyLjqNHn7gevC2gfVQBr87u
OgrvRWKmaIXka1HsALc5Z30uKr1wTcsquXk8S8Jq4WJWxu1ifFAle4ATJ77DWQp9M09Lx/BBRBw1
dxhOFA5JQhTS3/g+IRXW3aHU8es29QWXfKrQHYr6mFa6ZEwnTjYtBm3RGOIyr7IZ4u34Zvs26nNW
ZfUmOXCRUBWYVSg/Jsxx41U8UziuYjnGMSs7/DpWUZWSe3Phl3FDqSDSIWEcDQMiZdWYmwLsLQX9
GoaOVRn2bTaPXaRQdL+K53XMeRm5yfcHEY7TKuweTaIy9gO5DymK0Q5XVfBt7laIfoc44OTEcN+m
xAn36d3gFg0dlRYJor/MhI4ltGqnA8c0+bt2zCj0Y5sD59eOoQE+//pRRWa9rY14A+akqkrYOtZ+
T8Idb7oDLgL69vfcTTxLdgik+fLE867lvmu53n++5Z5Uz2dttIveCm1XrxvsotgskeMTV8hTytie
mjNyXZpFsoR5IhgBUY8zO0FS7JjSCB6zvu7gQoHNGCS4+oiqaC/CKSyw655mEsqMdShRyiVs7Ay5
krfGwyJd2W1hW28YbD+QWG3zwJKbmpzvCwo2ZrYJzeYzF9TUDM4qrHkpYwpmv46wulbqzNLqRjXT
6hxphckQw2XTgFh4ExYgCJYt4OUO7MW1aNiYYEYC7Xc79+ZhMVE4zxDJCAcki5G2ezlGdROkPFfM
SQDkTkWM9CbvFK+VpHU12zeQdpYglcW1ThCXR+9NopRn8CJKum6PlSNLysXJEnTY87rtRttDPk57
3hT2tPAYpxB1qdd8mIVwGuQrYdP+1GI2Vb6IZjc3zC2COhxTWL8vGez0gVRItYllZFPDfMpSgCVa
ktW/0Qa3npcBNtNfQ4vmKiTDv6YF+NENLZlOia/KwS5RtO/sa9ZK+UwRsRcFh2jCZmIXQ/h1qoI9
AZVwNGE6gn6BczTtbfPJbc5Z0ZVPrwzO0jFLI5y1W12ieSVbuKnjQgfzVlIPbKvU3Rj36qaYkj8n
U8pp/D8zRc8ncFLQDHQEfDiUFRjpeu15XKiIQxdKI+qPBCwcTO+AbIGzWPgMSQUnyOZXkAP9a2vO
8jBlDRs+tUtDJCjMRyoShOxAWzLZdwqzejZ3WZYsY2QyqqSuTK3aE3JA2Fj3wI6e2z0UQaqbbpK1
AYM7nn/ue1ZBk1Avcsr15vSQYu61NfBPr3xsMYNRbh82C5rc/4WKFbOqHW+G53Nv2RD9YbHMauVV
AcJKU0E3K/vXVOEVp1rbsZYsbrRz5SCKyxYDsVgQpXDeg/Q/mP+o8Jm9bdAT6pjvQm9FcNGgmUHa
QFZfsAsPpBukJU5g4WSJNpk0K+vabOmkvZZP1ue80i3kHnO21uws8X5FZxeLM1ecU4vn6ezMw46v
Le1EV0Nkj5cokKb5RsYEpurWaRunaBLWex7c/ECg78ET3B15QGtoWkPT4AkuhGCxZG9xel72kFPg
u6UUmGZOaeaYVk5p5ZR2ToHFWXZfklM60Kn0FQdcsekfD+W3GbCCy24/8qbqXM2t/wUAAP//AwBQ
SwMEFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJh
d2luZzEueG1sLnJlbHOEj80KwjAQhO+C7xD2btJ6EJEmvYjQq9QHCMk2LTY/JFHs2xvoRUHwsjCz
7DezTfuyM3liTJN3HGpaAUGnvJ6c4XDrL7sjkJSl03L2DjksmKAV201zxVnmcpTGKSRSKC5xGHMO
J8aSGtHKRH1AVzaDj1bmIqNhQaq7NMj2VXVg8ZMB4otJOs0hdroG0i+hJP9n+2GYFJ69elh0+UcE
y6UXFqCMBjMHSldnnTUtXYGJhn39Jt4AAAD//wMAUEsBAi0AFAAGAAgAAAAhALvlSJQFAQAAHgIA
ABMAAAAAAAAAAAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEArTA/
8cEAAAAyAQAACwAAAAAAAAAAAAAAAAA2AQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAVhHX
L74DAAB6CwAAHwAAAAAAAAAAAAAAAAAgAgAAY2xpcGJvYXJkL2RyYXdpbmdzL2RyYXdpbmcxLnht
bFBLAQItABQABgAIAAAAIQDhUTcfzwYAAOYbAAAaAAAAAAAAAAAAAAAAABsGAABjbGlwYm9hcmQv
dGhlbWUvdGhlbWUxLnhtbFBLAQItABQABgAIAAAAIQCcZkZBuwAAACQBAAAqAAAAAAAAAAAAAAAA
ACINAABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHNQSwUGAAAAAAUA
BQBnAQAAJQ4AAAAA
">
 <v:line id="Line_x0020_36" o:spid="_x0000_s2077" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="0,5" to="3970,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
 <v:rect id="Rectangle_x0020_35" o:spid="_x0000_s2078" style='position:absolute;
  left:3969;width:10;height:12;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQARKAHkxAAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9LawIx
EL4X/A9hBG8166Ot3RpFhYKXgo8e6m3cTHcXN5M1SXX11xuh4G0+vueMp42pxImcLy0r6HUTEMSZ
1SXnCr63n88jED4ga6wsk4ILeZhOWk9jTLU985pOm5CLGMI+RQVFCHUqpc8KMui7tiaO3K91BkOE
Lpfa4TmGm0r2k+RVGiw5NhRY06Kg7LD5Mwrm76P5cTXkr+t6v6Pdz/7w0neJUp12M/sAEagJD/G/
e6nj/MEb3J+JF8jJDQAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhABEoAeTEAAAA3AAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" fillcolor="black" stroked="f"/>
 <v:line id="Line_x0020_34" o:spid="_x0000_s2079" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="3979,5" to="9072,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="607" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image008.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1028" type="#_x0000_t75" style='width:453.6pt;height:.6pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><strong>Hepatobiliary disorders</strong></p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated liver enzymes</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pancreatitis, hepatitis, cholestatic jaundice</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:rect id="Rectangle_x0020_32"
 o:spid="_x0000_s2075" style='position:absolute;margin-left:181.55pt;
 margin-top:724.55pt;width:2.9pt;height:.6pt;z-index:-253009920;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:page;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#2d96d2" stroked="f">
 <w:wrap anchorx="page" anchory="page"/>
</v:rect><![endif]--><img width="4" height="1" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image009.gif" /><!--[if gte vml 1]><v:line id="Line_x0020_31"
 o:spid="_x0000_s2074" style='position:absolute;z-index:251685888;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:page;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page' from="42.35pt,712.1pt" to="42.35pt,725.5pt"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAMGeX0CACAACFBAAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWykVMGO2jAQvVfqP1i+Q2ISWIg2rKoE
9rJtV2L7AV7HJFYdO7JDAFX9945NAizl1OaQjO03b2aeZ/L4dKgl6rixQqsUk3GIEVdMF0KVKf7x
th7NMbItVQWVWvEUH7nFT8vPnx5pUhraVIIhYFA2oSmu2rZJgsCyitfUjnXDFZxttalpC0tTBoWh
e2CuZTAJw1lQU6Hw8kKV05ainRH/QCU1+8mLjKqOWqCULLne6XOU7P+ZaaK6Z9NsmlfjMmffuleD
RJFiUE7RGiTCQX/Qw2AZ3HiVF4LD1tQOr7dbdPAsR/f2HPzQInbaZJddVn2/g2XV6g4aAp8CgHEV
lB3UpnFRVZc587YWEkVDNS9CcRSRc1HXeOf6AsJbpHRWUVXyTUUb/nZsQAbvAmFBobOP1+G8oomF
yOh9/1UX4EB3rfbdcCPJfBJNF1OMQAEynUSEkPC+PuQhJHN/dC6bJo2x7TPXNXJGiiWU44PQ7sW2
p6sZIF4QvRZSevWlQvsUL0gcewerpSjcoYNZU75n0qCOSrgt/ziFIO4HmNE7VXiyitNi1dstFfJk
A14qxwc3Den01mkEfi3CxWq+msejeDJbjeIwz0df1lk8mq3JwzSP8izLyW+XGomTShQFVy67YRxJ
/Fev14IZbfW2HTNdB9BwgvFhJGEgSXgZSDXIEHxk9yVCssPXJ+2q9i0EBjt1VnAzgB7f/zDclF+v
l38AAAD//wMAUEsDBBQABgAIAAAAIQDhUTcfzwYAAOYbAAAaAAAAY2xpcGJvYXJkL3RoZW1lL3Ro
ZW1lMS54bWzsWc1v3EQUvyPxP4x8b7PfzUbdVNnNbgNt2ijZFvU4a8/a04w91sxs0r2h9oiEhCiI
A5W4cUBApVbiUv6aQBEUqf8Cb2ZsryfrkLSNoILmkLWff/O+35uvy1fuxQwdECEpT3pe/WLNQyTx
eUCTsOfdGo8urHpIKpwEmPGE9Lw5kd6V9fffu4zXfEbTCcciGEckJggYJXIN97xIqXRtZUX6QMby
Ik9JAt+mXMRYwasIVwKBD0FAzFYatVpnJcY08daBo9KMhgz+JUpqgs/EnmZDUIJjkH5zOqU+Mdhg
v64Rci4HTKADzHoe8Az44ZjcUx5iWCr40PNq5s9bWb+8gteyQUydMLY0bmT+snHZgGC/YWSKcFII
rY9a3UubBX8DYGoZNxwOB8N6wc8AsO+DpVaXMs/WaLXez3mWQPZxmfeg1q61XHyJf3NJ526/3293
M10sUwOyj60l/Gqt09poOHgDsvj2Er7V3xgMOg7egCy+s4QfXep2Wi7egCJGk/0ltA7oaJRxLyBT
zrYq4asAX61l8AUKsqHILi1iyhN1Uq7F+C4XIwBoIMOKJkjNUzLFPuTkAMcTQbEWgNcILn2xJF8u
kbQsJH1BU9XzPkxx4pUgL599//LZE3R0/+nR/Z+OHjw4uv+jZeSM2sJJWB714tvP/nz0MfrjyTcv
Hn5RjZdl/K8/fPLLz59XA6F8FuY9//Lxb08fP//q09+/e1gB3xB4UoaPaUwkukEO0S6PwTDjFVdz
MhGvNmIcYVoesZGEEidYS6ngP1SRg74xxyyLjqNHn7gevC2gfVQBr87uOgrvRWKmaIXka1HsALc5
Z30uKr1wTcsquXk8S8Jq4WJWxu1ifFAle4ATJ77DWQp9M09Lx/BBRBw1dxhOFA5JQhTS3/g+IRXW
3aHU8es29QWXfKrQHYr6mFa6ZEwnTjYtBm3RGOIyr7IZ4u34Zvs26nNWZfUmOXCRUBWYVSg/Jsxx
41U8UziuYjnGMSs7/DpWUZWSe3Phl3FDqSDSIWEcDQMiZdWYmwLsLQX9GoaOVRn2bTaPXaRQdL+K
53XMeRm5yfcHEY7TKuweTaIy9gO5DymK0Q5XVfBt7laIfoc44OTEcN+mxAn36d3gFg0dlRYJor/M
hI4ltGqnA8c0+bt2zCj0Y5sD59eOoQE+//pRRWa9rY14A+akqkrYOtZ+T8Idb7oDLgL69vfcTTxL
dgik+fLE867lvmu53n++5Z5Uz2dttIveCm1XrxvsotgskeMTV8hTytiemjNyXZpFsoR5IhgBUY8z
O0FS7JjSCB6zvu7gQoHNGCS4+oiqaC/CKSyw655mEsqMdShRyiVs7Ay5krfGwyJd2W1hW28YbD+Q
WG3zwJKbmpzvCwo2ZrYJzeYzF9TUDM4qrHkpYwpmv46wulbqzNLqRjXT6hxphckQw2XTgFh4ExYg
CJYt4OUO7MW1aNiYYEYC7Xc79+ZhMVE4zxDJCAcki5G2ezlGdROkPFfMSQDkTkWM9CbvFK+VpHU1
2zeQdpYglcW1ThCXR+9NopRn8CJKum6PlSNLysXJEnTY87rtRttDPk573hT2tPAYpxB1qdd8mIVw
GuQrYdP+1GI2Vb6IZjc3zC2COhxTWL8vGez0gVRItYllZFPDfMpSgCVaktW/0Qa3npcBNtNfQ4vm
KiTDv6YF+NENLZlOia/KwS5RtO/sa9ZK+UwRsRcFh2jCZmIXQ/h1qoI9AZVwNGE6gn6BczTtbfPJ
bc5Z0ZVPrwzO0jFLI5y1W12ieSVbuKnjQgfzVlIPbKvU3Rj36qaYkj8nU8pp/D8zRc8ncFLQDHQE
fDiUFRjpeu15XKiIQxdKI+qPBCwcTO+AbIGzWPgMSQUnyOZXkAP9a2vO8jBlDRs+tUtDJCjMRyoS
hOxAWzLZdwqzejZ3WZYsY2QyqqSuTK3aE3JA2Fj3wI6e2z0UQaqbbpK1AYM7nn/ue1ZBk1Avcsr1
5vSQYu61NfBPr3xsMYNRbh82C5rc/4WKFbOqHW+G53Nv2RD9YbHMauVVAcJKU0E3K/vXVOEVp1rb
sZYsbrRz5SCKyxYDsVgQpXDeg/Q/mP+o8Jm9bdAT6pjvQm9FcNGgmUHaQFZfsAsPpBukJU5g4WSJ
Npk0K+vabOmkvZZP1ue80i3kHnO21uws8X5FZxeLM1ecU4vn6ezMw46vLe1EV0Nkj5cokKb5RsYE
purWaRunaBLWex7c/ECg78ET3B15QGtoWkPT4AkuhGCxZG9xel72kFPgu6UUmGZOaeaYVk5p5ZR2
ToHFWXZfklM60Kn0FQdcsekfD+W3GbCCy24/8qbqXM2t/wUAAP//AwBQSwMEFAAGAAgAAAAhAJxm
RkG7AAAAJAEAACoAAABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHOE
j80KwjAQhO+C7xD2btJ6EJEmvYjQq9QHCMk2LTY/JFHs2xvoRUHwsjCz7DezTfuyM3liTJN3HGpa
AUGnvJ6c4XDrL7sjkJSl03L2DjksmKAV201zxVnmcpTGKSRSKC5xGHMOJ8aSGtHKRH1AVzaDj1bm
IqNhQaq7NMj2VXVg8ZMB4otJOs0hdroG0i+hJP9n+2GYFJ69elh0+UcEy6UXFqCMBjMHSldnnTUt
XYGJhn39Jt4AAAD//wMAUEsBAi0AFAAGAAgAAAAhALvlSJQFAQAAHgIAABMAAAAAAAAAAAAAAAAA
AAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAAAA
AAAAAAAAAAA2AQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAMGeX0CACAACFBAAAHwAAAAAA
AAAAAAAAAAAgAgAAY2xpcGJvYXJkL2RyYXdpbmdzL2RyYXdpbmcxLnhtbFBLAQItABQABgAIAAAA
IQDhUTcfzwYAAOYbAAAaAAAAAAAAAAAAAAAAAH0EAABjbGlwYm9hcmQvdGhlbWUvdGhlbWUxLnht
bFBLAQItABQABgAIAAAAIQCcZkZBuwAAACQBAAAqAAAAAAAAAAAAAAAAAIQLAABjbGlwYm9hcmQv
ZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHNQSwUGAAAAAAUABQBnAQAAhwwAAAAA
" strokeweight=".72pt">
 <w:wrap anchorx="page" anchory="page"/>
</v:line><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="2" height="19" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image010.gif" /></td></tr></tbody></table><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_27" o:spid="_x0000_s2070" style='position:absolute;left:0;
  text-align:left;margin-left:90.5pt;margin-top:16.25pt;width:453.6pt;height:.5pt;
  z-index:-251637760;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1810,325" coordsize="9072,10"
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:line id="Line_x0020_30" o:spid="_x0000_s2071" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1810,330" to="5779,330"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
  <v:rect id="Rectangle_x0020_29" o:spid="_x0000_s2072" style='position:absolute;
   left:5779;top:325;width:10;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:line id="Line_x0020_28" o:spid="_x0000_s2073" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="5789,330" to="10882,330"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="606" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br />Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fulminant hepatic necrosis</p><p>&nbsp;</p><p><strong>Skin and subcutaneous tissue disorders</strong></p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin reactions</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_23" o:spid="_x0000_s2066" style='width:453.6pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="9072,10" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:line id="Line_x0020_26" o:spid="_x0000_s2067" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="0,5" to="3970,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
 <v:rect id="Rectangle_x0020_25" o:spid="_x0000_s2068" style='position:absolute;
  left:3969;width:10;height:10;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCU8Zc5xAAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9LawIx
EL4X/A9hBG8161If3RpFC4KXQtUe6m3cjLuLm8maRF3765uC0Nt8fM+ZzltTiys5X1lWMOgnIIhz
qysuFHztVs8TED4ga6wtk4I7eZjPOk9TzLS98Yau21CIGMI+QwVlCE0mpc9LMuj7tiGO3NE6gyFC
V0jt8BbDTS3TJBlJgxXHhhIbei8pP20vRsHydbI8f77wx8/msKf99+E0TF2iVK/bLt5ABGrDv/jh
Xus4Px3D3zPxAjn7BQAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAJTxlznEAAAA3AAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" fillcolor="black" stroked="f"/>
 <v:line id="Line_x0020_24" o:spid="_x0000_s2069" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="3979,5" to="9072,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBfUdpbxQAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8Mw
DIXvg/4Ho8Fuq7Me1pHVLVuh7SCntYXuKGw1Do3lEHtJ9u+nw2A3iff03qfVZgqtGqhPTWQDT/MC
FLGNruHawPm0e3wBlTKywzYyGfihBJv17G6FpYsjf9JwzLWSEE4lGvA5d6XWyXoKmOaxIxbtGvuA
Wda+1q7HUcJDqxdF8awDNiwNHjvaerK343cwMByqr6FaRrSHS/Xu7W7fLMe9MQ/309srqExT/jf/
XX84wV8IrTwjE+j1LwAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQBfUdpbxQAAANwAAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
" strokeweight=".48pt"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="607" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1027" type="#_x0000_t75" style='width:453.6pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><strong>Renal and urinary disorders</strong></p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary retention, urinary incontinence</p><p><!--[if gte vml 1]><v:group id="Group_x0020_19"
 o:spid="_x0000_s2062" style='position:absolute;left:0;text-align:left;
 margin-left:90.85pt;margin-top:27.85pt;width:453.6pt;height:.5pt;z-index:-253008896;
 mso-position-horizontal-relative:page' coordorigin="1817,557" coordsize="9072,10"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:line id="Line_x0020_22" o:spid="_x0000_s2063" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="1817,561" to="5786,561"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
 <v:rect id="Rectangle_x0020_21" o:spid="_x0000_s2064" style='position:absolute;
  left:5786;top:556;width:10;height:10;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:line id="Line_x0020_20" o:spid="_x0000_s2065" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="5796,561" to="10889,561"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
 <w:wrap anchorx="page"/>
</v:group><![endif]--><img width="607" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image011.gif" />Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tubulointerstitial nephritis, renal impairment, renal failure.</p><p><strong>Reproductive system disorders</strong></p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Priapism, impotence, changes in ejaculation, dysmenorrhoea</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_15" o:spid="_x0000_s2058" style='width:453.6pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="9072,10" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:line id="Line_x0020_18" o:spid="_x0000_s2059" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="0,5" to="3970,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
 <v:rect id="Rectangle_x0020_17" o:spid="_x0000_s2060" style='position:absolute;
  left:3969;width:10;height:10;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:line id="Line_x0020_16" o:spid="_x0000_s2061" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="3979,5" to="9072,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="607" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:453.6pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><strong>General disorders</strong></p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Benign hyperthermia, disturbances in sweating/temperature regulation, fatigue, fever</p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden unexplained death</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_11" o:spid="_x0000_s2054" style='width:453.6pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="9072,10" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:line id="Line_x0020_14" o:spid="_x0000_s2055" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="0,5" to="3970,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
 <v:rect id="Rectangle_x0020_13" o:spid="_x0000_s2056" style='position:absolute;
  left:3969;width:10;height:10;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:line id="Line_x0020_12" o:spid="_x0000_s2057" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="3979,5" to="9072,5"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="607" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:453.6pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><strong>Investigations</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_7" o:spid="_x0000_s2050" style='position:absolute;left:0;
  text-align:left;margin-left:89.75pt;margin-top:14.55pt;width:454.35pt;
  height:.5pt;z-index:-251633664;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page'
  coordorigin="1795,291" coordsize="9087,10" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:line id="Line_x0020_10" o:spid="_x0000_s2051" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1795,296" to="5779,296"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
  <v:rect id="Rectangle_x0020_9" o:spid="_x0000_s2052" style='position:absolute;
   left:5764;top:291;width:10;height:10;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:line id="Line_x0020_8" o:spid="_x0000_s2053" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="5774,296" to="10882,296"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="607" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image012.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br />Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated creatine phosphokinase (CPK)</p><p>&nbsp;</p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyponatraemia.</p><p>Very rare events of ventricular tachycardia, cardiac arrest and QT prolongation which may be associated with Torsades De Pointes have been observed although there is no conclusive causal relationship to the use of this medicine.</p><p>&nbsp;</p><p>Adverse drug reactions from spontaneous reports and literature (frequency not known)</p><p>The following adverse drug reactions (ADRs) were derived from post-marketing experience with Leponex via spontaneous case reports and literature cases and have been categorized according to MedDRA system organ class (see Table 4). Because these reactions have been reported voluntarily from a population of uncertain size and are subject to confounding factors, these post-marketing ADRs have been categorized with a frequency of &ldquo;not known&rdquo; since it is not possible to reliably estimate their frequency. Adverse drug reactions are listed according to system organ classes in MedDRA. Within each system organ class, ADRs are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table 4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse drug reactions from spontaneous reports and literature (frequency not known)</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Sepsis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Drug rash with eosinophilia and systemic symptoms (DRESS), Angioedema, leukocytoclastic vasculitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pseudophaeochromocytoma</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Obesity</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p><p>Cholinergic syndrome, EEG changes, pleurothotonus (Pisa syndrome), restless legs syndrome (RLS)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p><p>Myocardial infarction (sometimes with fatal outcome), myocarditis (sometimes with fatal outcome), chest pain/angina pectoris, palpitations, atrial fibrillation, mitral valve incompetence associated with clozapine related cardiomyopathy</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Hypotension</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, </strong><strong>thoracic and mediastinal </strong><strong>disorders</strong></p><p>Pleural effusion, sleep apnoea syndrome, nasal congestion</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p><p>Megacolon and intestinal infarction/ischaemia (sometimes with fatal outcome), as well as intestinal necrosis, intestinal ulceration and bowel perforation with a possible fatal outcome,</p><p>diarrhoea, abdominal discomfort/heartburn/dyspepsia, colitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p><p>Hepatic steatosis, hepatic necrosis, hepatotoxicity, hepatic fibrosis, hepatic cirrhosis, liver disorders including those hepatic events leading to life-threatening consequences such as liver injury (hepatic, cholestatic and mixed), liver failure which may be fatal and liver transplant</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pigmentation disorder</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p><p>Rhabdomyolysis, muscle weakness, muscle spasms, muscle pain, systemic lupus erythematosus</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p><p>Renal failure, nocturnal enuresis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p><p>Retrograde ejaculation</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Polyserositis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td></tr><tr><td style="vertical-align:top"><p>Falls (associated with clozapine-induced seizures, somnolence, postural hypotension, motor and sensory instability)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>To reports any side effect(s):</strong></p><p>Saudi Arabia:</p><p>&sect;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&sect;&nbsp; Fax: +966-11-205-7662</p><p>&sect;&nbsp; SFDA Call Center: 19999</p><p>&sect;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&sect;&nbsp; Website: https://ade.sfda.gov.sa</p><p><strong>Other GCC States:</strong></p><p>&sect;&nbsp; Please contact the relevant competent authority.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In cases of acute intentional or accidental Leponex overdosage, for which information on the outcome is available, to date the mortality is about 12%. Most of the fatalities were associated with cardiac failure or pneumonia caused by aspiration and occurred at doses above 2000 mg. There have been reports of patients recovering from an overdose in excess of 10,000 mg. However, in a few adult individuals, primarily those not previously exposed to Leponex, the</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_5" o:spid="_x0000_s2050" style='width:456.25pt;height:.75pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="9125,15" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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==
">
 <v:line id="Line_x0020_6" o:spid="_x0000_s2051" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="0,7" to="9125,7"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".72pt"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="610" height="2" src="file:///C:/Users/nmusa/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:456.25pt;height:.75pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>ingestion of doses as low as 400 mg led to life-threatening comatose conditions and, in one case, to death. In young children, the intake of 50 mg to 200 mg resulted in strong sedation or coma without being lethal.</p><p>&nbsp;</p><p>Signs and symptoms</p><p>Drowsiness, lethargy, areflexia, coma, confusion, hallucinations, agitation, delirium, extrapyramidal symptoms, hyper-reflexia, convulsions; hypersalivation, mydriasis, blurred vision, thermolability; hypotension, collapse, tachycardia, cardiac arrhythmias; aspiration pneumonia, dyspnea, respiratory depression or failure.</p><p>&nbsp;</p><p>Treatment</p><p>There are no specific antidotes for Leponex.</p><p>Gastric lavage and/or the administration of activated charcoal within the first 6 hours after Leponex ingestion. (Peritoneal dialysis and hemodialysis are unlikely to be effective.) Symptomatic treatment under continuous cardiac monitoring, surveillance of respiration, monitoring of electrolytes and acid-base balance. The use of epinephrine should be avoided in the treatment of hypotension because of the possibility of a &lsquo;reverse epinephrine&rsquo; effect.</p><p>Close medical supervision is necessary for at least 5 days because of the possibility of delayed reactions.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.1&nbsp; Pharmacotherapeutic group:</p><p>ATC code: N05A H02</p><p>&nbsp;</p><p>Mechanism of action (MOA)</p><p>Leponex has been shown to be an antipsychotic agent that is different from classic antipsychotics.</p><p>In pharmacological experiments, the compound does not induce catalepsy or inhibit apomorphine- or amphetamine-induced stereotyped behavior. It has only weak dopamine receptor-blocking activity at D1, D2, D3 and D5 receptors, but shows high potency for the D4 receptor, in addition to potent anti-alpha-adrenergic, anticholinergic, antihistaminic, and arousal reaction-inhibiting effects. It has also been shown to possess antiserotoninergic properties.</p><p>&nbsp;</p><p>Pharmacodynamics (PD)</p><p>Clinically Leponex produces rapid and marked sedation, and exerts antipsychotic effects in patients with schizophrenia resistant to other antipsychotic agents. In such cases, Leponex has proven effective in relieving both positive and negative schizophrenic symptoms in short- and long-term trials.</p><p>Leponex is unique in that it produces virtually no major extrapyramidal reactions such as acute dystonia and tardive dyskinesia. Furthermore, parkinsonian-like side effects and akathisia are rare. In contrast to classical antipsychotics, clozapine produces little or no prolactin elevation, thus avoiding adverse effects such as gynecomastia, amenorrhea, galactorrhea, and impotence.</p><p>Potentially serious adverse reactions caused by Leponex therapy are granulocytopenia and agranulocytosis occurring at an estimated incidence of 3% and 0.7% respectively (see section WARNINGS AND PRECAUTIONS).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>The absorption of orally administered clozapine is 90% to 95%; neither the rate nor the extent of absorption is influenced by food.</p><p>Clozapine is subject to moderate first-pass metabolism, resulting in an absolute bioavailability of 50% to 60%.</p><p>&nbsp;</p><p><strong>Distribution</strong></p><p>In steady-state conditions, when given twice daily, peak blood levels occur on an average at 2.1 hours (range: 0.4 to 4.2 hours), and the volume of distribution is 1.6 L/kg. Clozapine is approximately 95% bound to plasma proteins.</p><p>&nbsp;</p><p><strong>Biotransformation/metabolism</strong></p><p>Clozapine is almost completely metabolized before excretion by CYP1A2 and 3A4, and to some extent by CYP2C19 and 2D6. Of the main metabolites only the desmethyl metabolite was</p><p>&nbsp;</p><p>&nbsp;</p><p>found to be active. Its pharmacological actions resemble those of clozapine, but are considerably weaker and of short duration.</p><p>&nbsp;</p><p><strong>Elimination</strong></p><p>Its elimination is biphasic, with a mean terminal half-life of 12 hours (range: 6 to 26 hours). After single doses of 75 mg the mean terminal half-life was 7.9 hours; it increased to 14.2 hours when steady-state conditions were reached by administering daily doses of 75 mg for at least 7 days</p><p>Only trace amounts of unchanged drug are detected in the urine and feces, approximately 50% of the administered dose being excreted as metabolites in the urine and 30% in the feces.</p><p>&nbsp;</p><p><strong>Linearity/non-linearity</strong></p><p>Dosage increases from 37.5 mg to 75 mg and 150 mg given twice daily were found to result during steady state in linearly dose-proportional increases in the area under the plasma concentration/time curve (AUC), and in the peak and minimum plasma concentrations.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical studies in treatment-resistant schizophrenia (Clozapine study 16 &amp; 30)</p><p>The first study was Study 16, a randomized, double-blind, multicenter, parallel group comparative trial of clozapine versus chlorpromazine (CPZ) in hospitalized patients (aged 18 to 65 years and of either sex) with treatment resistant schizophrenia (DSM-II criteria). 151 such patients were randomly assigned to either clozapine (150-900 mg) or chlorpromazine (300- 1800 mg) for 28 days with an optional extension up to 28 days (75 in clozapine group and 76 in chlorpromazine group). Efficacy was assessed by measuring mean change from baseline in the Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI) scores and the Nurses Observation Scale for Inpatient Evaluation (NOSIE-30). Throughout the study, and at endpoint, clozapine patients had a more rapid onset of action and showed significant improvement in BPRS items compared to chlorpromazine patients. At week 1, clozapine was statistically superior to CPZ in two items assessed: Motor retardation [0.67 vs. 0.12; p&lt;0.05] and blunted affect [0.93 vs. 0.34; p&lt;0.01]. At week 2, two more items also showed statistically significant improvements in clozapine group, emotional withdrawal [1.48 vs. 0.98; p&lt;0.01] and unusual thought content [2.06 vs. 1.45; p&lt;0.05]. At week 3, clozapine was statistically superior in 7 out of the 18 BPRS items assessed. At endpoint, clozapine showed statistically significant improvements in every item assessed. Results were similar for BPRS factors and CGI scores also. By week 2, statistically significant differences favoring clozapine were observed in the BPRS Total Score and maintained throughout the duration of study. Tests of comparative efficacy at endpoint showed clozapine to be significantly better for all five factors assessed: anxiety/depression (0.85 vs. 0.54; p&lt;0.05), anergia (1.15 vs. 0.72; p&lt;0.001), thought</p><p>disturbance (1.80 vs. 1.28; p &lt;0.01), activation (1.34 vs. 0.89; p&lt;0.01), and hostile/suspiciousness (1.26 vs. 0.74; p&lt;0.01)). At endpoint, clozapine showed statistically significant improvements in mean change in total BPRS score [22.53 vs. 14.64, p&lt;0.001] and CGI [1.95 vs. 1.33, p&lt;0.01]. Clozapine patients generally did better in the all NOSIE factors,</p><p>&nbsp;</p><p>&nbsp;</p><p>except for social competence. Mean change from baseline showed statistically significant differences favoring clozapine in the improvement of irritability at weeks 3 (6.28 vs. 0.67, p&lt;0.01) and week 4 (6.84 vs. 1.36, p&lt;0.05). For most of the factors, particularly, total patient assets, there was clear evidence of an early onset of therapeutic benefit with clozapine, thus corroborating BPRS data, although no statistical difference was observed. At endpoint, clozapine was superior to CPZ for the following NOSIE factors: social interest (4.14 vs. 3.24), personal neatness (3.19 vs. 2.26), irritability (3.04 vs. 0.60) and manifest psychosis (6.32 vs.</p><p>4.24) as well as total assets (20.54 vs. 16.66).</p><p>Second study was Study 30, a randomized, double-blind, multicenter, parallel group, 6-week, comparative study of clozapine versus chlorpromazine plus benztropine. The study population included 319 treatment-resistant schizophrenic patients, between the ages of 18-60 years, who met DSM-III criteria for schizophrenia, refractory to treatment. Eligible patients were randomly assigned to either clozapine (up to 900 mg/day) or chlorpromazine plus benztropine (up to 1800 mg/day of chlorpromazine, plus 6 mg/day of benztropine). Efficacy was assessed using the BPRS score, CGI scale, and NOSIE-30. At the end of 6 weeks, clozapine was significantly superior to chlorpromazine in all &ldquo;Positive&rdquo;, &ldquo;Negative&rdquo; and general symptoms of BPRS (p&lt;0.001) except &lsquo;Grandiosity&rsquo; and &lsquo;BPRS total score&rsquo;. Clozapine showed a significantly superior change in CGI scale compared to chlorpromazine starting at week 1 (p&lt;0.001). Clozapine was superior to chlorpromazine on all six NOSIE-30 factors and total assets starting at either week 1 or 2 (p &lt; 0.05 to 0.001). Clozapine was statistically significant in the following NOSIE factors, social competence, social interest and personal neatness, and total assets (p&lt;0.001), as well as irritability and motor retardation (p&lt;0.01 &lt;0.05, respectively).</p><p>&nbsp;</p><p>Clinical study in risk of recurrent suicidal behavior (InterSePT Trial)</p><p>The effectiveness of clozapine in reducing the risk of recurrent suicidal behavior was assessed in the International Suicide Prevention Trial (InterSePT), a prospective, randomized, open label, international, parallel-group comparison of clozapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder (DSM-IV) judged to be at risk for re-experiencing suicidal behavior, lasting for 24 months. A total of 956 patients were randomized to either clozapine (starting with 25 mg/day, titrated upwards to 200-900 mg/day) or olanzapine (5-20 mg/day). The primary efficacy measure was time to (1) a significant suicide attempt, including a completed suicide, (2) hospitalization due to imminent suicide risk (including increased level of surveillance for suicidality for patients already hospitalized), or (3) worsening of suicidality severity as demonstrated by &ldquo;much worsening&rdquo; or &ldquo;very much worsening&rdquo; from baseline in the CGI-SS-BP scale. Clozapine showed a statistically significant overall treatment effect compared to olanzapine for the primary efficacy measure (p=0.0309). Treatment effect for Type 1 events (a significant suicide attempt or hospitalization due to imminent suicide risk (including increased level of surveillance) was statistically significant in favor of clozapine (p=0.0316), with a hazard ratio [risk ratio] of 0.76 (95% C.I.: 0.58, 0.98). Similarly, the treatment effect for Type 2 events (worsening of suicidality severity as demonstrated by 7-point CGI-SS-BP change scale score of 6 or 7, or by implicit worsening of suicidality severity as demonstrated by occurrence of a Type 1 event) was statistically significant in favor of clozapine (p=0.0388), with a hazard ratio of 0.78 (95% C.I.: 0.61, 0.99). Probability (Standard Error, SE) of experiencing a Type 1 and Type 2 events was higher for olanzapine patients compared to</p><p>&nbsp;</p><p>&nbsp;</p><p>clozapine patients at all visits. At week 104, the clozapine treatment group demonstrated a significantly lower probability of both Type 1 (24% vs. 32%; 95% C.I. 2%, 14%) and Type 2</p><p>event (28% vs. 37%; 95% C.I.: 2%, 15%).</p><p>&nbsp;</p><p>Clinical study in psychosis in Parkinson&rsquo;s disease</p><p>A randomized, double-blind parallel group, multicenter trial was conducted to compare the efficacy of clozapine vs. placebo for the treatment of psychosis in Parkinson&#39;s disease (drug- induced psychosis unresponsive to usual management) and to compare the effect of clozapine vs. placebo on the motor function of patients with Parkinson&rsquo;s disease. Study participants included 60 male or female patients (32 clozapine, 28 placebo), who met the diagnosis criteria of idiopathic Parkinson&#39;s disease and with the following criteria of antiparkinsonian induced psychosis: psychotic symptoms for <u>&gt;</u> 2 weeks and requiring treatment (<u>&gt;</u> 4 at item P1 or P3 of the PANSS; MMS <u>&gt;</u> 20; no improvement of psychotic symptoms or unacceptable deterioration of motor function within a week despite usual therapeutic management; CGI-S <u>&gt;</u> 4. Patients received either clozapine or placebo for 4 weeks, starting with 10 days titration phase, up to the maximum dose of 50 mg (Period 2). All patients who completed period 2, received clozapine during 12 weeks with flexible dosage up to 150 mg/day (Period 3). Attempt of clozapine withdrawal (over 1 week) was made, with assessment visit 3 weeks later (Period 4). The mean change in CGI-S score (primary efficacy variable) was significantly greater in the clozapine group compared to the placebo group (-1.8 vs. -0.6; p=0.001) at the end of period 2. Significant improvement in CGI-S score was achieved at week 1 and maintained at all time points of period 2 for the clozapine group. At the end of Period 2, the mean change in the PANSS positive subscore (secondary efficacy variable) was significantly greater in the clozapine group than in the placebo group. Significant improvement in the PANSS positive subscores was obtained at week 1 and maintained at all subsequent time points. Reduction in scores of individual items were significant for all items. Clozapine treated patients continued to improve on both parameters during period 3. Improvement was slightly increased at end of period 3 for both the efficacy parameters, CGI-S (clozapine -2.5 vs. -1.8 for placebo) and PANSS (clozapine -7.7 vs.</p><p>-4.8 for placebo).</p><p>&nbsp;</p><p>Non-clinical safety data</p><p>Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential (for reproductive toxicity, see section WOMEN OF CHILD-BEARING POTENTIAL, PREGNANCY, BREASTFEEDING, AND FERTILITY).</p><p>&nbsp;</p><p>Mutagenicity</p><p>Clozapine and/or its metabolites were devoid of genotoxic potential when investigated for induction of gene mutations, chromosome aberrations and primary DNA-damage in a spectrum of <em>in vitro </em>mutagenicity tests. Likewise, no genotoxic activity was observed <em>in vivo </em>(bone marrow micronucleus test in mice).</p><p>&nbsp;</p><p>&nbsp;</p><p>Carcinogenicity</p><p>In Sprague-Dawley (CD) rats treated in the diet for 2 years, maximum tolerated doses of 35 mg/kg per day revealed no carcinogenic potential of clozapine. Likewise, no evidence of tumorigenic effects was obtained in two 1.5-year feeding studies in Charles River (CD) mice. In the first study, oral dose levels of up to 64 mg/kg per day were administered to males, and of up to 75 mg/kg per day to females respectively. In the second study, the highest dose for both sexes was 61 mg/kg per day.</p><p>&nbsp;</p><p>Reproductive toxicity</p><p>No embryotoxic or teratogenic potential of clozapine was observed in rats or rabbits at daily oral doses of up to 40 mg/kg. In male rats receiving the same dosages for 70 days prior to mating, fertility was unaffected.</p><p>In female rats, fertility as well as pre- and postnatal development of the offspring was not adversely affected by oral clozapine treatment prior to mating (up to 40 mg/kg per day). When rats were treated at the same dosages during the later part of pregnancy and during lactation, survival rates of the young from lactating dams were lowered and the young were hyperactive. However, there was no lasting effect on pup development after weaning.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate, Maize starch/ Corn starch, Povidone, Talc, Silica, colloidal anhydrous/ Colloidal silicone dioxide, Magnesium stearate, Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p><p>&nbsp;</p><p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&ordm; C.</p><p>Leponex should not be used after the date marked &ldquo;EXP&rdquo; on the pack. Leponex must be kept out of the reach and sight of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pack Size: 50 tablets</p><p>PVC/PVDC (colorless) blister packs or PVC/PDVC (opaque) blister packs Not all pack sizes may be marketed</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                7.	MARKETING AUTHORIZATION HOLDER
Mylan Pharma GmbH, Turmstrasse 24,
6312 Steinhausen, Switzerland
Tel. +41 (0)41 768 48 48
Fax. +41 (0)41 768 48 49
e-mail: info.ch@mylan.com

8.	MARKETING AUTHORIZATION NUMBERS
25 mg tablet: 2-5480-20
100 mg tablet: 1-5480-20

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>